{
  "name" : "moscow.sci-hub.se_4610_8450e8aea6cd34efee6e788d0a01869a_manivasagan2016.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : null,
    "authors" : [ "Panchanathan Manivasagan", "Junghwan Oh" ],
    "emails" : [ "jungoh@pknu.ac.kr" ],
    "sections" : [ {
      "heading" : null,
      "text" : "Page 1 of 45\nAc ce\npt ed\nM an\n1\nResearch on marine polysaccharide-based nanomaterials is emerging in nanobiotechnological 11 fields such as drug delivery, gene delivery, tissue engineering, cancer therapy, wound dressing, 12 biosensors, and water treatment. Important properties of the marine polysaccharides include 13 biocompatibility, biodegradability, nontoxicity, low cost, and abundance. Most of the marine 14 polysaccharides are derived from natural sources such as fucoidan, alginates, carrageenan, 15 agarose, porphyran, ulvan, mauran, chitin, chitosan, and chitooligosaccharide. Marine 16 polysaccharides are very important biological macromolecules that widely exist in marine 17 organisms. Marine polysaccharides exhibit a vast variety of structures and are still under-18 exploited and thus should be considered as a novel source of natural products for drug discovery. 19 An enormous variety of polysaccharides can be extracted from marine organisms such as algae, 20 crustaceans, and microorganisms. Marine polysaccharides have been shown to have a variety of 21\nPage 2 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n2\nbiological and biomedical properties. Recently, research and development of marine 22 polysaccharide-based nanomaterials have received considerable attention as one of the major 23 resources for nanotechnological applications. This review highlights the recent research on 24 marine polysaccharide-based nanomaterials for biotechnological and biomedical applications. 25\nKeywords: Marine polysaccharides, Nanomaterials, Biomedical applications, Nanoparticles, 26 Drug delivery. 27\nContents 28 1. Introduction.............................................................................................................................................3 29 2. Marine organisms as a source of polysaccharides ...............................................................................4 30 2.1. Marine algae .....................................................................................................................................4 31 2.2. Marine crustaceans...........................................................................................................................5 32 2.2.1. Chitin ..........................................................................................................................................5 33 2.2.2. Chitosan and Chitooligosaccharides .........................................................................................5 34 2.3. Marine microorganisms....................................................................................................................6 35 3. Marine polysaccharide-based nanomaterials .......................................................................................6 36 3.1. Fucoidan nanoparticles ....................................................................................................................7 37 3.2. Alginate nanoparticles ......................................................................................................................8 38 3.3. Carrageenan nanoparticles ............................................................................................................10 39 3.4. Agarose nanoparticles.....................................................................................................................12 40 3.5. Porphyran nanoparticles ................................................................................................................12 41 3.6. Nanofibers of Ulvan........................................................................................................................13 42 3.7. Mauran nanoparticles.....................................................................................................................14 43 3.8. Chitin nanoparticles........................................................................................................................14 44 3.9. Chitosan nanoparticles ...................................................................................................................16 45 3.10. Chitooligosaccharide nanoparticles .............................................................................................18 46 4. Biomedical and biotechnological applications of marine polysaccharide-based nanomaterials ...19 47 4.1. Biomedical applications ..................................................................................................................20 48 4.1.1. Antimicrobial activity ...............................................................................................................20 49 4.1.2. Drug delivery ............................................................................................................................21 50 4.1.3. Gene delivery ............................................................................................................................22 51\nPage 3 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n3\n4.1.4. Tissue engineering ...................................................................................................................23 52 4.1.5. Cancer therapy .........................................................................................................................23 53 4.1.6. Wound dressing........................................................................................................................24 54 4.2. Biotechnological applications.........................................................................................................25 55 4.2.1. Biosensors.................................................................................................................................25 56 4.2.2. Wastewater treatment...............................................................................................................26 57 5. Patents on marine polysaccharide-based nanomaterials...................................................................26 58 6. Conclusions ............................................................................................................................................27 59 Acknowledgements ...................................................................................................................................27 60 References..................................................................................................................................................27 61 62 1. Introduction 63 Marine polysaccharides have a great promise for applications in modern medicine and 64 nanobiotechnology and are well known in the biomedical engineering field for several 65 applications, namely gene delivery, drug delivery, tissue engineering, and wound dressing [1]. 66 Marine algae produce a variety of bioactive compounds with various structures and interesting 67 biological activities. Marine algae have been recognized as a rich source of sulfated 68 polysaccharides, including fucoidan, alginate, carrageenan, agarose, porphyran, and ulvan [2]. 69 Chitin, chitosan (CS), and oligosaccharides are derived from the exoskeleton of marine 70 crustaceans. Exopolysaccharides (EPS) produced by marine microorganisms are a complex 71 mixture of biopolymers mainly consisting of polysaccharides as well as nucleic acids, lipids, 72 proteins, and humic substances [3]. 73\nMarine polysaccharide-based nanomaterials have attracted attention as one of the most 74 important research in the recent years, particularly, in biomedical and chemical research because 75 of their good biocompatibility, biodegradability, nontoxicity, low cost, and abundance [4]. 76 Nowadays, pharmaceuticals based on marine bionanoparticles of polymers, liposomes, metals or 77\nPage 4 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n4\nmetal oxides, micelles, or dendrimers are actively being considered for combating different 78 diseases, including cancer and bacterial pathogens and for tissue engineering, drug delivery, gene 79 delivery, and wound healing [5]. Marine polysaccharides are easily processed into nanoparticles, 80 nanofibers, microparticles, scaffolds, membranes, gels, beads, and sponge forms, and these forms 81 have been used for various biomedical applications in cancer therapy, drug delivery, tissue 82 engineering, biosensors, wound dressing, and water treatment in the area of nanobiotechnology 83 [6]. This review focuses on marine polysaccharide-based nanomaterials for nanotechnological 84 and biomedical applications. 85\n2. Marine organisms as a source of polysaccharides 86 Marine polysaccharides are one of the major components of all living organisms. In 87 nature, marine polysaccharides are derived from various resources such as marine algae, 88 crustaceans, and microorganisms [4]. Marine organisms are recognized as the most abundant 89 source of polysaccharides. For decades, they have been used for various biological and 90 biomedical applications, namely anticoagulant [7], antioxidant [7], anti-inflammatory [8], 91 antiproliferative [7], antiviral [8], antitumor [9], antiparasitic [8], antiangiogenic [10], 92 antimetastatic [11], and immunomodulating [8] activities. The sulfated polysaccharides have 93 been of great interest in recent years because of their potential to produce novel bioactive 94 compounds [12]. 95\n2.1. Marine algae 96 Marine algae are excellent candidates for sulfated polysaccharides and have received a 97 greater interest as natural resources of marine natural products. The sulfated polysaccharides 98 extracted from marine algae have received considerable attention in the nutraceutical, 99 cosmeceutical, and pharmaceutical fields [13]. The marine algae are divided into three major 100\nPage 5 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n5\ntypes: green algae (Chlorophyceae), red algae (Rhodophyceae), and brown algae 101 (Phaeophyceae). Laminarin, fucoidan, and alginates are naturally occurring biopolymers 102 extracted from marine brown algae. Carrageenans, agarose, and porphyran are sulfated 103 polysaccharides extracted from red seaweeds [14]. Ulvan is a natural polysaccharide isolated 104 from green algae [15]. 105\n2.2. Marine crustaceans 106\n2.2.1. Chitin 107 Chitin is one of the most abundant natural polymers on earth and is found in the 108 exoskeletons of marine crustaceans and cell walls of marine fungi [5]. The major sources of 109 chitin are shrimp, crab, and lobster shells, which are the most abundantly available waste 110 products of the seafood industry. This biopolymer is easily processed into nanoparticles, 111 nanofibers, microparticles, membranes, scaffolds, gels, beads, and sponge forms in the 112 biomedical field because of their excellent biocompatibility, high biodegradability and low 113 toxicity [16]. These properties, find various biomedical applications such as targeted drug 114 delivery, gene delivery, wound dressing, and tissue engineering in the area of nanotechnology 115 [17]. 116\n2.2.2. Chitosan and Chitooligosaccharides 117 CS is a naturally occurring biopolymer isolated by the N-deacetylation of chitin. It is the 118 main constituent of the exoskeletons of marine crustaceans, including shrimp and crab. Recently, 119 CS is of a special interest for applications in the chemical, nutraceutical, and pharmaceutical 120 industries [18]. Chitooligosaccharides (COSs) are the depolymerization products of chitin or CS 121 by enzymatic and acidic hydrolysis methods. These methods have attracted special interest 122 because of their ease of control and safety. Several enzymes have been used to prepare COSs. 123\nPage 6 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n6\nThey are highly water soluble and nontoxic have good biocompatibility, excellent 124 biodegradability, and low cost [19]. CS and COSs have a great promise in recent years because 125 of their biomedical applications, namely antimicrobial activity [20], tissue engineering [21], 126 wound healing [22], drug delivery [23], antitumor effects [24], and hypocholesterolemic effects 127 [25]. 128\n2.3. Marine microorganisms 129 Marine microbial EPS are natural biopolymers primarily consisting of polysaccharides 130 produced by bacteria [26], cyanobacteria [27], actinobacteria [28], and fungi [29]. Nowadays, 131 EPS have attracted increasing attention in pharmaceutical, cosmeceutical, and nutraceutical 132 industries as well as in wastewater treatment and detergent applications [30]. Marine microbial 133 polysaccharides have been a growing interest for biological activities such as antiviral, anti-134 inflammatory, and antitumor activates [31]. Raveendran et al. [1] reported an extremophilic 135 bacterial polysaccharide, mauran (MR), for the first time as a novel biocompatible and stable 136 biomaterial to the world of nanotechnology, pharmaceutics and biomedical technology. 137 Manivasagan et al. [32] studied the production of polysaccharide-based bioflocculant for the 138 green synthesis of silver nanoparticles by Streptomyces sp. The biosynthesized silver 139 nanoparticles can be extended as an alternative for the development of novel bactericidal 140 bionanomaterials for wastewater treatment and biotechnological applications. 141\n3. Marine polysaccharide-based nanomaterials 142 Marine polysaccharide-based nanomaterials have attracted considerable attention of the 143 nanotechnology scientists in recent years because of their good biocompatibility, high 144 biodegradability, low cost, and nontoxic nature, and have received interest as novel carriers for 145 imaging and therapeutic agents due to their unique physicochemical properties. Marine 146\nPage 7 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n7\npolysaccharides are the most abundant polysaccharide, simple, stable, inexpensive, nontoxic, 147 safe, hydrophilic, biocompatible, and biodegradable [33]. These properties are of special interest 148 in the field of nanotechnology and have a promising future as biomaterials. In recent years, many 149 researchers have investigated on polysaccharides-based nanomaterials for biomedical application 150 such as antimicrobial activity, drug delivery, gene delivery, tissue engineering, cancer therapy, 151 and wound dressing (Fig. 1) (Table. 1) [34-36]. 152\n3.1. Fucoidan nanoparticles 153 Fucoidan (1) (Fig. 2) is a naturally occurring sulfated polysaccharide extracted from 154 marine brown seaweeds [37, 38]. Similar fucan sulfates were obtained from marine invertebrates 155 [39]. Fucoidan is an excellent drug candidate for pharmaceutical applications. Recently, fucoidan 156 has been investigated because of its various biological properties such as anticoagulant [40], 157 antiviral [41], antiangiogenic, antitumor, anti-inflammatory, [42], antioxidant [43], 158 antiproliferative and immunomodulating properties [41]. In the past few years, a large number of 159 researchers of novel bioactive compounds have taken special interest in fucoidans [44]. 160 Fucoidans have been investigated in the biosynthesis of metal nanoparticles and has been used 161 for cancer treatment and drug delivery. 162 Lia et al. [45] reported the synthesis and characterization of fucoidan-coated poly 163 (isobutylcyanoacrylate) nanoparticles. The nanoparticles were prepared by anionic emulsion 164 polymerization and by redox radical emulsion polymerization of isobutylcyanoacrylate using 165 fucoidan as a novel coating biomaterial. They exhibited in vitro potent cytotoxic activity against 166 J774 macrophage and NIH-3T3 fibroblast cell lines. The IC50 (2 µg/mL) of anionic emulsion 167 polymerization nanoparticles on the J774 macrophages was low. Fucoidans are extracted from 168\nPage 8 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n8\ntwo different types of marine algae Cladosiphon okamuranus and Kjellamaniella crassifolia. 169 Fucoidans were used for the green synthesis of gold nanoparticles [46]. 170 Leung et al. [47] reported the biosynthesis of silver nanoparticles using 171 carboxymethylated curdlan or fucoidan as reducing and stabilizing agents. Fucoidan was isolated 172 from marine brown seaweed Cladosiphon okamuranus and encapsulated in nanoparticles using 173 liposomes as nanocarriers. These nanoparticles showed potent in vitro anticancer activity against 174 osteosarcoma [48]. To prepare the chemotherapeutic agent-loaded nanoparticles, 175 hydrophobically modified fucoidan was synthesized by the acetylation of fucoidan. Doxorubicin 176 (DOX was used as a model chemotherapeutic agent, and the drug was loaded in the acetylated 177 fucoidan nanoparticles (11) (Fig. 3). The nanoparticles were characterized by their morphology 178 and drug release properties [49]. 179\n3.2. Alginate nanoparticles 180 Alginate (2) (Fig. 2) is a natural polysaccharide extracted from brown seaweeds and has 181 been widely investigated and used for biomedical applications because of their excellent 182 biocompatibility, low cost, low toxicity, and mild gelation [50]. Nowadays, a large number of 183 studies for alginate-based nanoparticles have raised greater interest in the medical field because 184 of their potential applications such as in insulin delivery [51] and antifungal and antitubercular 185 drugs [52]. 186 Sarmento et al. [51] prepared insulin-loaded nanoparticles using alginate ionotropic pre-187 gelation followed by CS polyelectrolyte complexation. In their study, particles in nanometer size 188 range were obtained under optimized conditions with a loading capacity of 14.3%. In another 189 study using dextran polysaccharide as the complexing agent, again, insulin was loaded in 190 alginate–dextran nanospheres via nanoemulsion dispersion followed by triggered in situ gelation. 191\nPage 9 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n9\nThe resulting particles ranged in size from 267 nm to 2.76 µm. Particles were prepared with a 192 unimodal size distribution, and insulin encapsulation efficiency of 82.5% was reached. Anh et al. 193 [53] reported an effective γ-irradiation method for the preparation of gold nanoparticles using 194 alginate, a natural polysaccharide, as a stabilizer. The obtained alginate-stabilized gold 195 nanoparticles were characterized using UV–vis spectroscopy and transmission electron 196 microscopy. The results showed that γ-irradiation technique is suitable for the production of 197 alginate-stabilized gold nanoparticles with controllable size and high purity. The alginate-198 stabilized gold nanoparticles were spherical in nature, with particle size ranging from 5 to 40 nm. 199 Yang and Pan [54] studied the hydrothermal synthesis of silver nanoparticles using 200 sodium alginate as a reducing and stabilizing agent. It showed that the temperature and 201 incubation time of the reaction played major roles under suitable concentrations of sodium 202 alginate and precursor Ag+ in the formation of silver nanoparticles with specific shapes. In 203 general, a low temperature and short incubation time of reaction were shown to result in the 204 formation of nanospheres, and increasing the temperature and incubation time of reaction were 205 favorable for the formation of nanoplates. 206\nZhang et al. [55] studied DOX-loaded glycyrrhetinic acid-modified alginate nanoparticles 207 (ALG NPs) for liver tumor chemotherapy. The nanoparticles showed strong liver-targeting 208 efficiency owing to passive targeting via the enhanced permeability and retention effects and the 209 active targeting efficiency of glycyrrhetinic acid (GA). Cardiac toxicity was reduced after the 210 administration of DOX/GA-ALG NPs. In particular, DOX/GA-ALG NPs improved the 211 antitumor activity of DOX against liver tumors in situ. GA-ALG/DOX-ALG NPs were planned 212 as a drug delivery system with pH-sensitive and liver-targeted properties. These results showed 213 that GA-ALG/DOX-ALG NPs may act as a therapeutic agents in liver cancer treatment [56]. 214\nPage 10 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n10\nThe therapeutic failure of tuberculosis is mostly due to patient non-compliance, which is 215 recognized to require multidrug administration daily or several times a week for at least 6 216 months. Nanoparticle-based drug delivery systems are appropriate for mycobacterial infections 217 such as tuberculosis. Interestingly, the biomedical application of nanoparticles-based drug 218 delivery systems offers a new perspective for the treatment of tuberculosis [57]. Ahmad et al. 219 [58] studied the pharmacokinetics and tissue distribution of free and alginate-encapsulated 220 antitubercular drugs in mice at various doses. ALG NP-encapsulating isoniazid (INH), 221 rifampicin (RIF), pyrazinamide (PZA), and ethambutol (EMB) were orally administered to mice. 222 The average size of particles was found to be 235.5 ± 0.0 nm, with drug encapsulation abilities of 223 70%–90%, 80%–90%, and 88%–95% for INH, RIF, and EMB, respectively. 224\n3.3. Carrageenan nanoparticles 225 Carrageenan is a naturally occurring biopolymer obtained from marine red algae, 226 Kappaphycus sp. and Eucheuma sp. The chemical structure of carrageenan is made of D-227 galactose and anhydrogalactose units combined by glycosidic linkages and containing ester 228 sulfate groups. Depending upon the extraction procedures and resources, carrageenan they are 229 divided into three types, kappa (κ) (3), iota (ι) (4), and lambda (λ) (5) (Fig. 2), mostly differing in 230 the substitution degree of the sulfate group. Among the three types of carrageenan, κ- and ι-231 carrageenan have a high gelling efficiency, with the former being rigid and firm and the latter 232 being elastic and soft in nature [59]. λ-Carrageenan is a non-gelling polysaccharide [60]. Daniel-233 da-Silva et al. [61] investigated the biosynthesis of magnetite nanoparticles using carrageenan. κ, 234 ι, and λ carrageenans have been investigated that the particle size morphology and chemical 235 stability of nanocomposite. De Souza et al. [62] reported the antioxidant activities of six types of 236 sulfated polysaccharides extracted from marine brown and red seaweeds; λ carrageenan and 237\nPage 11 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n11\nfucoidan exhibited strong antioxidant activity. Stiles et al. [63] reported the inhibitory effect of λ-238 carrageenan and a mixture of sulfated polysaccharides isolated from red seaweeds against feline 239 herpesvirus (FHV)-1 in an in vitro. The IC50 of λ-carrageenan against FHV-1 was found to be 5 240 µg/mL [63]. 241\nGrenha et al. [64] developed a novel formation of carrageenan and CS nanoparticles as a 242 suitable drug delivery system. These nanoparticles are produced in hydrophilic conditions using 243 very mild procedure and avoiding the use of organic solvents and other aggressive conditions. 244 These nanoparticles were demonstrated as appropriate vehicles that can offer sustained and 245 controlled for the drug delivery system. The nanoparticles showed low toxicity against fibroblast 246 cell lines as well as good biocompatibility and high safety. These nanoparticles were indicated to 247 be good candidates for biomedical applications such as drug delivery and tissue engineering. 248 Rodrigues et al. [65] reported the production of CS, carrageenan, and tripolyphosphate 249 nanoparticles with smaller size, strong positive surface, and stability and were used for 250 application in mucosal delivery of macromolecules. Hezaveh and Muhamad [66] reported the 251 effect of metallic nanoparticles on gastrointestinal release from modified κ-carrageenan 252 hydrogels. The effect of genipin cross-linking and metallic nanoparticle loading was also 253 investigated, and the most suitable drug delivery system was successfully introduced. These 254 metallic nanoparticles seem to be a great promising strategy to significantly improve 255 gastrointestinal tract-controlled drug delivery. Salgueiro et al. [67] demonstrated the effect of 256 incorporating spherical and rod-shaped gold nanoparticles in the microstructure and 257 thermomechanical properties of κ-carrageenan hydrogels and in the release kinetics and 258 mechanism of methylene blue from κ-carrageenan nanocomposites. Hydrogel nanocomposites 259\nPage 12 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n12\nshowed enhanced viscoelastic properties as compared to neat κ-carrageenan, when using either 260 gold nanospheres and gold nanorods. 261\n3.4. Agarose nanoparticles 262 Agarose (6) (Fig. 2) is a natural biopolymer extracted from red seaweeds, Gracilaria sp. 263 and Gelidium sp. Agarose is a linear biopolymer made up of repeating units of agarobiose, which 264 is a disaccharide made up of D-galactose and 3,-6-anhydro-L-galactopyranose. Agarose is 265 commonly used in the biochemistry, molecular biology, and biotechnology fields for the 266 isolation of biomolecules, particularly DNA by electrophoresis. Agarose is generally used for its 267 gel-forming property to make semiconductor and metal nanoparticles. These nanoparticles 268 exhibited strong antibacterial activity against Escherichia coli. Interestingly, the agarose 269 composite films can be quickly converted to carbon-metal composites by carbonizing the films 270 in nitrogen atmosphere [68]. Kattumuri et al. [69] reported the use of agarose-stabilized gold 271 nanoparticles for the detection of micromolar concentrations of DNA nucleosides using surface-272 enhanced Raman spectroscopic detection. These results indicate that agarose-stabilized gold 273 nanoparticles yield higher surface-enhanced Raman spectroscopic detection for DNA 274 nucleosides, which is used for on-chip biosensing applications. 275\n3.5. Porphyran nanoparticles 276 Porphyran (7) (Fig. 3) is a naturally occurring sulfated polysaccharide extracted from 277 marine red seaweed, Porphyra vietnamensis [70]. Porphyran comprises the hot-water-soluble 278 portion of the cell wall, is the major constituent (40%–50%) of the marine red seaweeds, and has 279 nutritional value. Porphyran is made up of anionic disaccharide units consisting of 3-linked D-280 galactosyl residues alternating with 4-linked 3,6-anhydro-L-galactose and 6-sulfate residues. The 281 pharmaceutical purposes of porphyran extracted from different porphyra species were reported in 282\nPage 13 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n13\nvarious structural and functional studies. It was interesting to note the reports on the anticancer 283 and antioxidant activities of porphyran [71]. Venkatpurwar et al. [72] reported the biosynthesis 284 of gold nanoparticles using a porphyran and subsequent loading of DOX. The porphyran-capped 285 gold nanoparticles (Fig. 4A) and DOX-loaded gold nanoparticles were evaluated using suitable 286 techniques to study morphology, size, surface charge, and drug-loading efficiency. 287 Venkatpurwar et al. [73] demonstrated that the toxicology profile comprises in vitro cytotoxic 288 activity and in vivo sub-acute oral toxicity of newly synthesized gold nanoparticles using new 289 sulfated polysaccharide porphyran obtained from marine red seaweed. In vitro cytotoxic activity 290 of porphyran-reduced gold nanoparticles (10, 50, or 100 µM) was performed employing normal 291 monkey kidney cell line, which showed a non-toxic nature of nanoparticles. 292\n3.6. Nanofibers of Ulvan 293 Ulvan (8) (Fig. 3) is a complex anionic sulfated polysaccharide isolated from the cell 294 walls of marine green algae (Ulvales, Chlorophyta). They are still under-exploited, are an 295 abundant resource, and have a low cost of production. The major components of ulvan are 296 sulfated, xylose, rhamnose, glucuronic, and iduronic acids. The potential applications of ulvan 297 have been investigated as an antioxidant, antitumor, anticoagulant, and immune modulator [15]. 298 Presently, ulvan isolated from marine green algae, Ulva rigida has been used for the preparation 299 of nanofibers. Nanofibers are of special interest in the biomedical engineering field because of 300 their potential applications in drug delivery, wound dressing, and tissue engineering. Ulvan is a 301 good candidate for nanofiber fabrication and has been successfully introduced into 302 nanobiotechnology. 303 Toskas et al. [74] reported the spinnability of ulvan-rich, isolated polysaccharides from 304 marine green seaweed Ulva rigida that was used for the fabrication of nanofibers. The nanofiber 305\nPage 14 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n14\nability of an ulvan-rich extract in combination with its interesting physicochemical and 306 biological properties can lead to a new biomedical application such as drug delivery, wound 307 dressing and tissue engineering. Kikionis et al. [75] prepared novel fibrous biocomposites of 308 ulvan using the electrospinning technique. These nanofibrous matrices represent novel promising 309 biomaterials in biomedical applications, including tissue engineering, wound dressing, and drug 310 delivery systems. 311\n3.7. Mauran nanoparticles 312 Mauran is a naturally occurring sulfated polysaccharide with high sulfate, phosphate, and 313 uronic acid content. It is isolated from a moderately halophilic bacterium, Halomonas maura, 314 and has been used for the biosynthesis of metal nanoparticles. It has been reported that they 315 constitute mannose, galactose, glucose, and glucuronic acid. Moreover, they are well known for 316 their viscoelasticity. The pseudoplastic and thixotropic natures of mauran make it an ideal 317 molecule for material science applications [76]. Raveendran et al. [1] reported the synthesis of 318 sulfated polysaccharide-based nanoparticles as a good biocompatible material for anticancer 319 activity, drug delivery and bioimaging. 320\n3.8. Chitin nanoparticles 321 Chitin (9) (Fig. 3) is also a biopolymer that is abundant in nature [77]. It is isolated from 322 crab, shrimp, and lobster shells as a by-product of the seafood industry. Worldwide, several 323 million tons of chitin are generated annually as waste by the seafood industry [78]. Chitin has 324 been successfully prepared by several methods such as enzymatic methods, methods using 325 hydrolytic conditions of boiling HCl and vigorous stirring, and methods using chitin whiskers of 326 slender parallelepiped rods. Chang et al. [79] reported the preparation of presumably functional 327 chitin nanoparticles and their application as reinforcing fillers in polymeric matrices. 328\nPage 15 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n15\nCarboxymethyl chitin (CMC) is a nontoxic, water-soluble anionic derivative of chitin 329 containing carboxyl groups. It is used as a constituent of wound-healing dressings, exhibits good 330 biocompatibility and can be synthesized from chitin [80]. Dev et al. [81] prepared CMC 331 nanoparticles using the cross-linking approach with FeCl3 and CaCl2 that was used for controlled 332 drug delivery applications. These nanoparticles exhibited in vitro cytotoxic activity against 333 mouse L929 cell lines. The nanoparticles showed strong antibacterial activity against 334 Staphylococcus. Smitha et al. [82] demonstrated novel amorphous chitin nanoparticles (AC NPs) 335 that were widely used for colon cancer drug delivery. Paclitaxel (PTX) was used as the main 336 chemotherapeutic agent, and the drug was loaded into AC NPs through ionic cross-linking 337 approach using pentasodium tripolyphosphate. The PTX-loaded AC NPs had an average size of 338 200 ± 50 nm. These nanoparticles were confirmed to be hemocompatible and in vitro drug 339 release exhibited a sustained release of PTX. 340 Drug delivery into intracellular compartments is a big challenge in the present treatment 341 systems. To deliver drugs into the intracellular compartments, numerous drugs encapsulated in 342 nanoparticles and microparticles were prepared, which showed enhanced efficacy in delivering 343 the drug into the intracellular compartments [83]. Smitha et al. [84], designed rifampicin (RIF)-344 loaded AC Nps for intracellular delivery of RIF inside polymorphonuclear leukocytes. The RIF 345 molecules entrapped in the amorphous chitin polymer remained in the bioactive form, and the 346 antibacterial activity was retained upon their release. Furthermore, sustained drug delivery could 347 reduce dosing frequency, lower toxicity, enable long-term treatment, and prevent potential side 348 effects related to the free drug. RIF-loaded AC NPs could be used for an effective delivery of 349 RIF into the intracellular compartments of the polymorphonuclear leukocytes to resolve serious 350 bacterial infections faster and more effectively. 351\nPage 16 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n16\n3.9. Chitosan nanoparticles 352 CS (10) (Fig. 3) is a naturally occurring biopolymer family of linear polysaccharide that 353 is composed of glucosamine and N-acetyl glucosamine units via β-(1→ 4) linkages randomly or 354 block-spread throughout the polymer chain, depending on the extraction procedures to derive CS 355 from chitin. The deacetylation degree is well defined as the molar ratio of glucosamine to N-356 acetyl glucosamine, which is a significant factor determining its physicochemical properties and 357 industrial applications [59]. After the deacetylation process, CS is able to dissolve in an acidic 358 medium and becomes the only sulfated polysaccharide that possesses a high density of positive 359 charges, owing to the protonation of amino groups on its backbone. Besides this unique 360 characteristic, CS has been evidenced to have various other intrinsic properties, namely good 361 biocompatibility and biodegradability and non-toxicity [85]. Nowadays, CS has attracted 362 considerable scientific interest and nanotechnological attention in the biomedical sector for 363 various applications, including tissue engineering [86], drug delivery [87] and nutrition [88]. 364 Rather et al. [89] reported the CS- and CS-gold nanoconjugates of salmon leutinizing 365 hormone releasing hormone (LHRH) of desired size, dispersity, and zeta potential were 366 synthesized and evaluated at half the dose rate against full dose of bare LHRH for their 367 reproductive efficacy in female fish, Cyprinus carpio. Because the reaction involves complex 368 formation between oppositely charged species (negatively charged groups of the pentasodium 369 tri-polyphosphate and the positively charged amino groups of CS), CS undergoes ionic gelation 370 and precipitates to form spherical particles. The functional structure of CS nanoparticles is 371 depicted in Fig. 4B. 372 Janes et al. [90] reported the potential of CS nanoparticles as a delivery system for DOX. 373 Evaluation of the cytotoxic activity of DOX-loaded cell lines suggested that addition of dextran 374\nPage 17 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n17\nsulfate enabled the maintenance of cytotoxic activity, which is relative to free DOX, whereas 375 DOX complexed with CS before nanoparticle formation exhibited slightly decreased activity. 376 Mitra et al. [91] prepared dextran-DOX encapsulated in CS nanoparticles using reverse 377 microemulsion and studied their antitumor activity in murine tumor models. De Campos et al. 378 [92] demonstrated the potential use of CS nanoparticles as a novel carrier for the targeted 379 delivery of drugs to the ocular mucosa, using the immunosuppressive peptide cyclosporin A as a 380 model drug. CS nanoparticles cross-linked with glutaraldehyde have been prepared in AOT/n 381 hexane reverse micellar system. The particle size of these CS nanoparticles was mainly 382 influenced by the degree of cross-linking. The particle size at infinite dilution was 30 nm, when 383 10% of the amine groups in the polymeric chains were cross-linked and it shoots up to 110 nm 384 when all the amine groups were cross-linked [93]. 385 Qi et al. [94] showed the in vitro antibacterial activity of CS nanoparticles and copper-386 loaded nanoparticles against pathogenic microorganisms. These nanoparticles showed 387 antibacterial activity against E. coli, S. choleraesuis, S. typhimurium, and S. aureus. These results 388 indicated that CS nanoparticles and copper-loaded nanoparticles could inhibit the growth of 389 pathogenic bacteria. Gan et al. [95] studied polyanion-initiated gelation process in fabricating 390 CS–tripolyphosphate nanoparticles in the size range from 100 to 250 nm, intended to be used as 391 carriers for the delivery of gene or protein macromolecules. Katas and Alpar [96] developed CS 392 nanoparticles as a delivery system for double-stranded small interfering RNA (siRNA). In vitro 393 studies in two different types of cell lines such as CHO K1 and HEK 293 have exposed that the 394 preparation technique of siRNA association to CS plays a major part on the silencing affect. 395 Chitosan–tripolyphosphate nanoparticles with entrapped siRNA were shown to be good vehicles 396\nPage 18 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n18\nfor siRNA delivery compared with CS–siRNA complexes, possibly because of their excellent 397 binding capacity and high loading efficiency. 398 Min et al. [97] showed that hydrophobically modified glycol chitosan (HGC) 399 nanoparticles encapsulated camptothecin (CPT) with a high loading efficiency and CPT–HGC 400 nanoparticles demonstrating sustained CPT release maintained the stability of the active lactone 401 form of CPT by protecting the lactone from hydrolysis. Compared with free CPT, CPT–HGC 402 nanoparticles exhibited a longer circulation time in the blood, a better targeting of the drug to 403 tumor tissue and a substantial enhancement of antitumor activity. Ali et al. [98] demonstrated 404 the synthesis and characterization of CS and silver-loaded CS nanoparticles for antimicrobial 405 textile applications. Silver loading on the synthesized CS nanoparticles exhibited synergistic 406 antibacterial activity against S. aureus. These results suggested that the preparation of novel CS 407 nanoparticles for antimicrobial textile applications as CS in nano form is highly active due to 408 their high surface area and very low concentration. Lima et al. [99] showed the evaluation of the 409 hemagglutination activity of CS nanoparticles using human erythrocytes. CS nanoparticles 410 presented hemolytic activity ranging from 186.20%–223.12%, whereas neutralized solutions 411 ranged from 2.56%–72.54% compared with distilled water. 412\n3.10. Chitooligosaccharide nanoparticles 413 COS, a low molecular weight depolymerization product of CS, has attracted increasing 414 attention in pharmaceutical and biomedical applications because it not only is water-soluble, 415 biocompatible, biodegradable, and nontoxic in nature, but also demonstrates unique biological 416 activities such as antimicrobial, immune-enhancing, and antitumor activities. COS is particularly 417 suitable for developing polymer-drug conjugate because of its availability for coupling with the 418 primary amino groups and hydroxyl groups of each polymer subunit and the cationic nature that 419\nPage 19 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n19\nallows ionic crosslinking [100]. Hydrophobically-modified amphiphilic COS derivatives can 420 fabricate self-assembled polymeric nanoparticles and therefore facilitate drug delivery in cancer 421 therapy by improving the solubility of insoluble drugs, drug targeting, and absorption [101]. 422 Lopez-Cruz et al. [102] prepared magnetic nanoparticles consisting of iron oxide cores modified 423 with covalently linked COS that was colloidally stable in water and buffers. The enhanced 424 colloidal stability of these COS-coated nanoparticles, owing to the covalent linking of COS to 425 the nanoparticle, makes them attractive for biomedical applications. 426 Bae et al. [103] prepared CS oligosaccharide-stabilized ferrimagnetic iron oxide 427 nanocubes (Chito-FIONs) as an effective heat nanomediator for cancer hyperthermia. Chito-428 FIONs showed superior magnetic heating efficiency with a high specific loss power value (2614 429 W/g) compared with commercial superparamagnetic Feridex nanoparticles (83 W/g). They 430 exhibited strong antitumor activity on an animal tumor model without any severe toxicity. Liu et 431 al. [104] investigated a novel multidentate dithiolane lipoic acid and phosphorylcholine 432 conjugated CS oligosaccharide derivative that can serve as a ligand to effectively stabilize gold 433 nanoparticles. These nanoparticles could be widely used for biological applications. Lin et al. 434 [105] prepared the COS nanoparticles by the formation of polyelectrolyte complexes. These 435 nanoparticles exhibited strong inhibition of the proliferation of HeLa and B16 melanoma cells. 436 Lu et al. [106] prepared the synthesis of COS-based multidentate ligand for ultrastable, 437 cytotoxicity and biocompatible nanoparticles. 438\n4. Biomedical and biotechnological applications of marine polysaccharide-based 439 nanomaterials 440 Marine polysaccharide-based nanomaterials are considered as nanomedicine presenting 441 high potential for diagnosis and therapeutical purposes. Recently, the studies on the 442\nPage 20 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n20\nbiotechnological and biomedical applications of marine natural products, particularly marine 443 polysaccharides, are attracting more and more attention all over the world [107]. Marine 444 polysaccharides and their lower molecular weight oligosaccharide derivatives have been shown 445 to possess a variety of biomedical activities. Some of the important nanobiotechnological 446 applications of polysaccharide-based nanomaterials are in the field of antimicrobial activity, drug 447 delivery, gene delivery, tissue engineering, cancer therapy, wound dressing biosensors and water 448 treatment (Fig. 5). 449\n4.1. Biomedical applications 450\n4.1.1. Antimicrobial activity 451 The ability of pathogenic microorganisms to resist antimicrobial agents has evolved since 452 the start of antimicrobial therapy and it still constitutes a serious problem in clinical practice, 453\nthus limiting the arsenal of drugs available and requiring the development of new substances to 454\ncombat them [108]. In this context, inorganic agents have been considered excellent candidates 455\nfor research because of their high antimicrobial potential [109]. Among them, silver compounds 456\nand their derivatives are one of the most extensively studied, and a current focus of research 457\ninvolving this metal is the synthesis and evaluation of their antimicrobial activity in the form of 458\nnanoparticles [110, 111]. Shukla et al. [111] reported the synthesis and characterization of silver 459 nanoparticles and nanocomposite material using gar extracted from the red alga Gracilaria dura. 460\nThe antibacterial effect of silver nanoparticles showed greater bactericidal effect, with 99.9% 461\nreduction of bacteria over the control value. The silver nanocomposite film with proven 462\nantibacterial activity may find applications in food preservation and wound dressing. 463\nVenkatpurwar et al. [112] reported the green synthesis of silver nanoparticles using marine 464 polysaccharide isolated from marine red algae, Porphyra vietnamensis. The dose-dependent 465\nPage 21 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n21\neffect of biosynthesized silver nanoparticles revealed strong antibacterial activity against gram-466 negative bacteria compared with gram-positive bacteria. 467\n4.1.2. Drug delivery 468 The potential use of nanobiotechnology in medicine and more efficient drug delivery is 469 set to spread rapidly. Recently, many bioactive compounds are under-exploited for targeted drug 470 delivery, although more efficient for cancer treatment. Interestingly, biomedical sciences are 471 using nanomaterials to reduce toxicity, dosing frequency, and avoiding potential side effects and 472 until now do not understand that delivery systems themselves may impose risks to the patient 473 [113]. De Salamanca et al. [114] studied the in vitro and in vivo effects of CS nanoparticles as a 474 novel drug delivery system for the ocular mucosa. Fuente et al. [115] developed a delivery 475 platform based on CS nanoparticles, which suits the requirements of the topical ocular route. 476 These nanoparticles have been exactly modified for the delivery of hydrophilic and lipophilic 477 drugs as well as polynucleotides onto the eye surface. Venkatpurwar et al. [72] studied the 478 biosynthesis of gold nanoparticles using porphyran and the subsequent loading of DOX. The 479 DOX-loaded gold nanoparticles demonstrated strong cytotoxicity on LN-229 cell line. 480\nWu et al. [116] reported a nanocarrier based on CS and fucoidan for oral delivery of 481 berberine (Ber). A sulfonated fucoidan, fucoidan–taurine (FD–Tau) conjugate, was synthesized 482 and characterized by Fourier transform infrared spectroscopy. The FD–Tau conjugate was self-483 assembled with berberine and CS to form Ber-loaded CS/FD–Tau complex nanoparticles with 484 high drug–loading efficiency. A schematic diagram of the preparation of Ber-loaded CS/FD–Tau 485 nanoparticles is shown in Fig 6A. 486\nPage 22 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n22\n4.1.3. Gene delivery 487 Gene therapy is the use of genes for correcting genetic disorders. In case of gene 488 delivery, the plasmid DNA has to be successfully introduced into the target cells, which should 489 get transcribed and the genetic information should ultimately be translated into the corresponding 490 protein. To achieve this aim, a number of hurdles are to be overcome by the gene delivery device 491 [100]. Increasingly, nucleic acids are being applied for both vaccination and therapeutic gene 492 expression, and CS nanoparticles have been recommended as promising nonviral gene carriers. 493 The core-shell structured CS-ALG NPs (Fig. 6B) were made using a water-in-oil reverse 494 microemulsion template. These nanoparticles were used to encapsulate a plasmid DNA for gene 495 delivery via the cell endocytosis pathway [117]. However, as has been stated above, CS–DNA 496 nanoparticles may be readily formed by complex coacervation between the positively charged 497 amine groups on CS and negatively charged phosphate groups on DNA [118]. Protection of 498 encapsulated plasmid DNA from nuclease attack offered by CS nanoparticles was confirmed by 499 assessing degradation in the presence of DNase I, and the transformation of the plasmids with 500 incubated nanoparticles were studied by β-galactosidase assay. Model pDNA existed as a 501 mixture of both supercoiled (84.2%) and open circular (15.8%) forms. 502\nThe use of siRNA as an important therapeutic agent for the treatment of several diseases 503 is limited owing to its quick degradation and low intracellular association in vitro and in vivo. 504 Lee et al. [119] investigated that CS–polyguluronate nanoparticles exhibited low cytotoxicity and 505 were useful in delivering siRNA to HEK 293 FT and HeLa cells. These nanoparticles have a 506 great promise for siRNA delivery because of their low cytotoxicity and ability to transport 507 siRNA into cells [119]. 508\nPage 23 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n23\n4.1.4. Tissue engineering 509 Tissue engineering is one of the fastest growing multidisciplinary field connecting the 510 development of bioartificial implants and/or foster remodeling of tissues with the purpose of 511 repairing, replacing, maintaining, or enhancing tissue or organ function. Bioartificial constructs 512 mostly consist of living cells and biomaterials; therefore, tissue engineering draws from both 513 living cell and biomaterial science and technology. Noh et al. [120] studied the cytocompatibility 514 of chitin nanofibers. Chitin nanofiber matrix produced by electrospinning was introduced to 515 tissue engineering. The study showed that the chitin nanofibers could be potential candidates for 516 the cell attachment and spreading of normal human keratinocytes and fibroblasts. 517 Shalumon et al. [121] prepared a novel fibrous membrane of carboxymethyl chitin 518 (CMC)/poly (vinyl alcohol) (PVA) blend using electrospinning technique. Cytotoxicity of the 519 nanofibrous scaffold was evaluated using human mesenchymal stem cells by the MTT assay. 520 These results indicate that the nanofibrous CMC/PVA scaffold supports cell adhesion/attachment 521 and proliferation, and hence, these scaffolds are useful for tissue engineering applications. Peter 522 et al. [122] prepared CS–gelatin/nanophase hydroxyapatite composite scaffolds by blending CS 523 and gelatin with nanophase hydroxyapatite. The scaffolds exhibited well swelling characteristic, 524 which could be modulated by varying the ratio of chitosan and gelatin. The biomedical response 525 of MG-63 cells on nanocomposite scaffolds was superior in terms of improved cell attachment, 526 higher proliferation, and spreading compared with CS–gelatin scaffold. 527\n4.1.5. Cancer therapy 528 Cancer is a dreadful human disease. Nanomaterials are frequently considered in the 529 parenteral injection of aqueous insoluble drugs for drug targeting issues because their particle 530 sizes are less than 1000 nm. DOX incorporated nanoparticles prepared using methoxy poly 531\nPage 24 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n24\n(ethylene glycol)-grafted carboxymethyl chitosan nanoparticles (CMCPED) were developed to 532 study antitumor activity. Because DOX has positive amine groups, it can interact with the 533 carboxymethyl group of CMCPED and can form nanoparticles. The antitumor activity of DOX-534 incorporated nanoparticles in vitro was tested with DOX-resistant C6 glioma. These 535 nanoparticles exhibited higher cytotoxicity to DOX alone [123]. CS nanoparticles were used as 536 vehicles for the mitotic inhibitor paclitaxel. PTX-loaded CS nanoparticles were prepared by a 537 solvent evaporation and emulsification cross-linking method. Cytotoxic activity exhibited that 538 the paclitaxel-loaded CS nanoparticles had higher cell toxicity than individual paclitaxel, and 539 confocal microscopy analysis confirmed strong cellular uptake efficiency [124]. Lee et al. [49] 540 studied the DOX-loading fucoidan acetate nanoparticles for immunotherapy and chemotherapy 541 in cancer treatment. Acetate nanoparticles have important functions, namely immunomodulation 542 and drug efflux pump inhibition [49]. 543\n4.1.6. Wound dressing 544 Nowadays, the research and development of antibacterial treatment-resistant pathogens is 545 a major problem, and the newly designed wound dressing has provided a main breakthrough for 546 the treatment of infection and wounds. Recently, many researchers have focused on developing 547 novel antibacterial treatments to treat wounds infected with antibacterial treatment-resistant 548 pathogens. Currently, silver nanoparticles have come up as a more efficient bactericidal agent 549 and are finding various biomedical applications ranging from silver-based dressing to silver-550 coated therapeutic devices [125]. A lot of studies have investigated the use of CS scaffolds and 551 membranes to treat patients with wounds, deep burns, etc. Chen et al. [126] prepared the 552 collagen-CS complex nanofibers by electrospinning. These nanofibers are well known for their 553 positive effect on wound healing. Madhumathi et al. [22] have incorporated silver nanoparticles 554\nPage 25 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n25\ninto chitin scaffolds for wound-healing applications. These α-chitin/nanosilver composite 555 scaffolds were found to possess good antibacterial activity against pathogenic bacteria, combined 556 with excellent blood-clotting ability. These in vitro results indicated that α-chitin/nanosilver 557 composite scaffolds could be useful for wound-healing applications. 558\n4.2. Biotechnological applications 559\n4.2.1. Biosensors 560 Biosensors have been of special interest in recent years because of their advantageous 561 properties as analytical tools such as simple, portable, low cost, well-established, and laboratory-562 based methods as well as allows miniaturization [127]. The CS nanofibrous membrane was 563 explored as support for enzyme immobilization owing to the characteristics of good 564 biocompatibility, high surface, and large porosity. The CS nanofibrous membrane was up to 63.6 565 mg/g, and the activity retention of the immobilized lipase was 49.8% less than the optimum 566 condition. This system can be used for biosensors [128]. Wang et al. [129] investigated a new 567 electrochemical tyrosinase biosensor for determining phenolic compounds on the basic of the use 568 of a glassy carbon electrode modified with tyrosinase–Fe3O4 magnetic nanoparticles-CS 569 nanobiocomposite film. The tyrosinase biosensor shows good repeatability and stability. Such 570 novel tyrosinase biosensor exhibits great promise for fast, simple, and eco-friendly methods of 571 phenolic contaminants in environmental samples [129]. Chauhan et al. [130] developed an 572 amperometric biosensor for the determination of glutathione (GSH) by covalently immobilizing 573 a glutathione oxidase (GSHOx) onto the surface of gold-coated magnetic nanoparticles 574 (Fe@AuNPs)-modified Pt electrode. CS was used to introduce amino groups onto the surface of 575 Fe@AuNPs. The present study exhibited that GSHOx/CS/Fe@Au-modified Pt electrode was an 576 excellent candidate for the construction of highly sensitive glutathione biosensor. 577\nPage 26 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n26\n4.2.2. Wastewater treatment 578 CS has received considerable attention in water treatment because of the presence of 579 reactive amino groups. Chitin and CS have been widely studied in the removal of heavy metal 580 ions from wastewater [131]. Fierro et al. [132] investigated and found that the CS bead-581 immobilized algae system with Scenedesmus sp. was more effective in removing phosphate and 582 nitrate from water than the conventional free cell system. Manivasagan et al. [32] reported the 583 biosynthesis of silver nanoparticles using polysaccharide-based bioflocculant by Streptomyces 584 sp. MBRC-91. The biosynthesized silver nanoparticles exhibited strong antibacterial activity in 585 sewage water, and this result can make a new avenue in the wastewater treatment. 586\n5. Patents on marine polysaccharide-based nanomaterials 587 More than 50 patents are available on marine polysaccharides-based nanomaterials and 588 their applications. In all these patents, only very few patents specifically claim that 589 nanocomposite materials based on metallic nanoparticles were stabilized with branched 590 polysaccharides, in particular alditolic or aldonic mono-saccharidic and oligosaccharidic 591 derivatives of CS, and their preparation was obtainable with the aqueous solutions of these 592 polysaccharides in the presence or absence of reducing agents. The properties associated with the 593 nanometric dimensions and the presence of biological signals on polymeric chains may be 594 exploited in applications with antimicrobial activities and molecular biosensors [133]. The 595 nanocomposite materials in the form of three-dimensional structure formed by a polymeric 596 matrix consisting of a polysaccharidic composition of neutral or anionic polysaccharides and 597 branched cationic polysaccharides, in which metallic nanoparticles are uniformly dispersed and 598 stabilized, has also been claimed [134]. 599\nPage 27 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n27\n6. Conclusions 600 In the present review, marine polysaccharides-based nanomaterials are an excellent 601 source for nanotechnological applications such as drug delivery, gene delivery, tissue 602 engineering, cancer therapy, wound dressing, biosensors, and water treatment. This method is 603 simple, inexpensive, eco-friendly, and highly recommended to be used in the large-scale 604 production of bionanomaterials. Marine polysaccharides are highly stable, safe, biocompatible, 605 biodegradable, nontoxic, low cost, and abundant. However, most of the industrial applications 606 are still at the laboratory level. In addition, in vivo studies and clinical applications are needed to 607 develop new commercial nanoproducts. Marine polysaccharide-based nanomaterials have a great 608 promise in biomedicine, fabric, food, and pharmaceutical industries for the future. 609\nAcknowledgements 610 This research was supported by a grant from Marine Biotechnology Program (20150220) 611 funded by the Ministry of Oceans and Fisheries, Republic of Korea. 612\nReferences 613 [1] S. Raveendran, B. Dhandayuthapani, Y. Nagaoka, Y. Yoshida, T. Maekawa, D.S. Kumar, 614 Carbohydr. Polym. 92 (2013) 1225-1233. 615 [2] K. Senni, J. Pereira, F. Gueniche, C. Delbarre-Ladrat, C. Sinquin, J. Ratiskol, G. Godeau, A.-616 M. Fischer, D. Helley, S. Colliec-Jouault, Mar. Drugs, 9 (2011) 1664-1681. 617 [3] P. Laurienzo, Mar. Drugs, 8 (2010) 2435-2465. 618 [4] S. Raveendran, Y. Yoshida, T. Maekawa, D.S. Kumar, Nanomed-Nanotechnol. 9 (2013) 605-619 626. 620 [5] R. Jayakumar, D. Menon, K. Manzoor, S. Nair, H. Tamura, Carbohydr. Polym. 82 (2010) 621 227-232. 622\nPage 28 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n28\n[6] R. Jayakumar, M. Prabaharan, S. Nair, H. Tamura, Biotechnol. Adv. 28 (2010) 142-150. 623 [7] L. Costa, G. Fidelis, S. Cordeiro, R. Oliveira, D. Sabry, R. Câmara, L. Nobre, M. Costa, J. 624 Almeida-Lima, E. Farias, Biomed. Pharmacother. 64 (2010) 21-28. 625 [8] T. Toida, C. Amornrut, R.J. Linhardt, Trends Glycosci. Glyc. 15 (2003) 29-46. 626 [9] X. Wu, D. Chen, W. Indian Med. J. 55 (2006) 270-273. 627 [10] S. Gustafson, Glycobiology 7 (1997) 1209-1214. 628 [11] C.R. Parish, C. Freeman, K.J. Brown, D.J. Francis, W.B. Cowden, Cancer Res. 59 (1999) 629 3433-3441. 630 [12] M. Luscher-Mattli, Antivir. Chem. Chemoth. 11 (2000) 249-259. 631 [13] D. Renn, Trends Biotechnol. 15 (1997) 9-14. 632 [14] V.L. Campo, D.F. Kawano, D.B. da Silva, I. Carvalho, Carbohydr. Polym. 77 (2009) 167-633 180. 634 [15] M. Lahaye, A. Robic, Biomacromolecules 8 (2007) 1765-1774. 635 [16] C. Pillai, W. Paul, C.P. Sharma, Prog. Polym. Sci. 34 (2009) 641-678. 636 [17] H. Ehrlich, E. Steck, M. Ilan, M. Maldonado, G. Muricy, G. Bavestrello, Z. Kljajic, J. 637 Carballo, S. Schiaparelli, A. Ereskovsky, Int. J. Biol. Macromol. 47 (2010) 141-145. 638 [18] W. Xia, P. Liu, J. Zhang, J. Chen, Food Hydrocolloid. 25 (2011) 170-179. 639 [19] S.-B. Lin, Y.-C. Lin, H.-H. Chen, Food Chem. 116 (2009) 47-53. 640 [20] X. Zhao, W. Xia, Food Res. Dev. 27 (2006) 157-160. 641 [21] K. Madhumathi, N. Binulal, H. Nagahama, H. Tamura, K. Shalumon, N. Selvamurugan, S. 642 Nair, R. Jayakumar, Int. J. Biol. Macromol. 44 (2009) 1-5. 643 [22] K. Madhumathi, P.S. Kumar, S. Abhilash, V. Sreeja, H. Tamura, K. Manzoor, S. Nair, R. 644 Jayakumar, J. Mater. Sci-Mater. M. 21 (2010) 807-813. 645\nPage 29 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n29\n[23] R. Jayakumar, N. Nwe, S. Tokura, H. Tamura, Int. J. Biol. Macromol. 40 (2007) 175-181. 646 [24] W. Xia, J. Chinese Ins. Food Sci. Technol. 3 (2003) 77-81. 647 [25] F.-H. Liao, M.-J. Shieh, N.-C. Chang, Y.-W. Chien, Nutr. Res. 27 (2007) 146-151. 648 [26] P. Manivasagan, S.-K. Kim, In: Se-Kwon Kim (Eds), Adv. Food Nutr. Res. Burlington: 649 Academic Press, 72 (2014) pp. 79-94. 650 [27] Z. Chi, C. Su, W. Lu, Bioresource Technol. 98 (2007) 1329-1332. 651 [28] P. Manivasagan, P. Sivasankar, J. Venkatesan, K. Senthilkumar, K. Sivakumar, S.-K. Kim, 652 Int. J. Biol. Macromol. 59 (2013) 29-38. 653 [29] C. Sun, J.-W. Wang, L. Fang, X.-D. Gao, R.-X. Tan, Life Sci. 75 (2004) 1063-1073. 654 [30] A. Mishra, B. Jha, Bioresource Technol. 100 (2009) 3382-3386. 655 [31] M. Zhang, L. Zhang, P.C.K. Cheung, V.E.C. Ooi, Carbohydr. Polym. 56 (2004) 123-128. 656 [32] P. Manivasagan, K.-H. Kang, D.G. Kim, S.-K. Kim, Int. J. Biol. Macromol. 77 (2015) 159-657 167. 658 [33] J.W. Lee, J.H. Park, J.R. Robinson, J. Pharm. Sci. 89 (2000) 850-866. 659 [34] V. Sinha, R. Kumria, Int. J. Pharm. 224 (2001) 19-38. 660 [35] T.F. Vandamme, A. Lenourry, C. Charrueau, J. Chaumeil, Carbohydr. Polym. 48 (2002) 661 219-231. 662 [36] C. Lemarchand, R. Gref, P. Couvreur, Eur. J. Pharm. Biopharm. 58 (2004) 327-341. 663 [37] K.-J. Kim, O.-H. Lee, B.-Y. Lee, Life Sci. 86 (2010) 791-797. 664 [38] E. O’Connell, P. Murray, C. Piggott, F. Hennequart, M. Tuohy, J. Appl. Phycol. 20 (2008) 665 557-565. 666 [39] O. Berteau, B. Mulloy, Glycobiology 13 (2003) 29-40. 667\nPage 30 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n30\n[40] C.F. Becker, J.A. Guimarães, P.A. Mourão, H. Verli, J. Mol. Graph. Model. 26 (2007) 391-668 399. 669 [41] K. Hayashi, T. Nakano, M. Hashimoto, K. Kanekiyo, T. Hayashi, Int. Immunopharmacol. 8 670 (2008) 109-116. 671 [42] A. Cumashi, N.A. Ushakova, M.E. Preobrazhenskaya, A. D'Incecco, A. Piccoli, L. Totani, 672 N. Tinari, G.E. Morozevich, A.E. Berman, M.I. Bilan, Glycobiology 17 (2007) 541-552. 673 [43] J. Wang, Q. Zhang, Z. Zhang, Z. Li, Int. J. Biol. Macromol. 42 (2008) 127-132. 674 [44] B. Li, F. Lu, X. Wei, R. Zhao, Molecules 13 (2008) 1671-1695. 675 [45] M. Lira, N. Santos-Magalhães, V. Nicolas, V. Marsaud, M. Silva, G. Ponchel, C. Vauthier, 676 Eur. J. Pharm. Biopharm. 79 (2011) 162-170. 677 [46] K. Lirdprapamongkol, W. Warisnoicharoen, S. Soisuwan, J. Svasti, Am. J. Appl. Sci. 7 678 (2010) 1038-1042. 679 [47] T.C.-Y. Leung, C.K. Wong, Y. Xie, Mater. Chem. Phys. 121 (2010) 402-405. 680 [48] R. Kimura, T. Rokkaku, S. Takeda, M. Senba, N. Mori, Mar. Drugs 11 (2013) 4267-4278. 681 [49] K.W. Lee, D. Jeong, K. Na, Carbohydr. Polym. 94 (2013) 850-856. 682 [50] M. Rajaonarivony, C. Vauthier, G. Couarraze, F. Puisieux, P. Couvreur, J. Pharm. Sci. 82 683 (1993) 912-917. 684 [51] B. Sarmento, A. Ribeiro, F. Veiga, D. Ferreira, R. Neufeld, J. Nanosci. Nanotechno. 7 685 (2007) 2833-2841. 686 [52] Z. Ahmad, S. Sharma, G.K. Khuller, Nanomed-Nanotechnol. 3 (2007) 239-243. 687 [53] N.T. Anh, D. Van Phu, N.N. Duy, B.D. Du, N.Q. Hien, Radiat. Phys. Chem. 79 (2010) 405-688 408. 689 [54] J. Yang, J. Pan, Acta Mater. 60 (2012) 4753-4758. 690\nPage 31 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n31\n[55] C. Zhang, W. Wang, T. Liu, Y. Wu, H. Guo, P. Wang, Q. Tian, Y. Wang, Z. Yuan, 691 Biomaterials 33 (2012) 2187-2196. 692 [56] H. Guo, Q. Lai, W. Wang, Y. Wu, C. Zhang, Y. Liu, Z. Yuan, Int. J. Pharm. 451 (2013) 1-693 11. 694 [57] R. Pandey, G. Khuller, Indian J. Exp. Biol. 44 (2006) 357-366. 695 [58] Z. Ahmad, R. Pandey, S. Sharma, G.K. Khuller, Int. J. Antimicrob. Ag. 27 (2006) 409-416. 696 [59] Y. Luo, Q. Wang, Int. J. Biol. Macromol. 64 (2014) 353-367. 697 [60] Y.A. Shchipunov, J. Colloid Interf. Sci. 268 (2003) 68-76. 698 [61] A.L. Daniel-da-Silva, T. Trindade, B.J. Goodfellow, B.F. Costa, R.N. Correia, A.M. Gil, 699 Biomacromolecules 8 (2007) 2350-2357. 700 [62] M.C.R. De Souza, C.T. Marques, C.M.G. Dore, F.R.F. da Silva, H.A.O. Rocha, E.L. Leite, 701 J. Appl. Phycol. 19 (2007) 153-160. 702 [63] J. Stiles, L. Guptill-Yoran, G.E. Moore, R.M. Pogranichniy, Invest. Ophth. Vis. Sci. 49 703 (2008) 1496-1501. 704 [64] A. Grenha, M.E. Gomes, M. Rodrigues, V.E. Santo, J.F. Mano, N.M. Neves, R.L. Reis, J. 705 Biomed. Mater. Res. A. 92 (2010) 1265-1272. 706 [65] S. Rodrigues, A.M.R. da Costa, A. Grenha, Carbohydr. Polym. 89 (2012) 282-289. 707 [66] H. Hezaveh, I.I. Muhamad, Carbohydr. Polym. 89 (2012) 138-145. 708 [67] A.M. Salgueiro, A.L. Daniel-da-Silva, S. Fateixa, T. Trindade, Carbohydr. Polym. 91 709 (2013) 100-109. 710 [68] K. Datta, B. Srinivasan, H. Balaram, M. Eswaramoorthy, J. Chem. Sci. 120 (2008) 579-586. 711 [69] V. Kattumuri, M. Chandrasekhar, S. Guha, K. Raghuraman, K.V. Katti, K. Ghosh, R. Patel, 712 Appl. Phys. Lett. 88 (2006) 153114-153113. 713\nPage 32 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n32\n[70] D. Sahoo, P. Baweja, N. Kushwah, J. Appl. Phycol. 18 (2006) 279-286. 714 [71] M.-J. Kwon, T.-J. Nam, Life Sci. 79 (2006) 1956-1962. 715 [72] V. Venkatpurwar, A. Shiras, V. Pokharkar, Int. J. Pharm. 409 (2011) 314-320. 716 [73] V. Venkatpurwar, V. Mali, S. Bodhankar, V. Pokharkar, Toxicol. Environ. Chem. 94 (2012) 717 1357-1367. 718 [74] G. Toskas, R.-D. Hund, E. Laourine, C. Cherif, V. Smyrniotopoulos, V. Roussis, 719 Carbohydr. Poly. 84 (2011) 1093-1102. 720 [75] S. Kikionis, E. Ioannou, G. Toskas, V. Roussis, J. Appl. Polym. Sci. 132 (2015). 721 [76] S. Raveendran, A.C. Poulose, Y. Yoshida, T. Maekawa, D.S. Kumar, Carbohydr. Polym. 91 722 (2013) 22-32. 723 [77] S. Wibowo, G. Velazquez, V. Savant, J.A. Torres, Bioresource Technol. 96 (2005) 665-671. 724 [78] R. Hejazi, M. Amiji, J. Control. Release. 89 (2003) 151-165. 725 [79] P.R. Chang, R. Jian, J. Yu, X. Ma, Carbohydr. Polym. 80 (2010) 420-425. 726 [80] Y. Song, H. Onishi, T. Nagai, Biol. Pharm. Bull. 16 (1993) 48-54. 727 [81] A. Dev, J.C. Mohan, V. Sreeja, H. Tamura, G. Patzke, F. Hussain, S. Weyeneth, S. Nair, R. 728 Jayakumar, Carbohydr. Polym. 79 (2010) 1073-1079. 729 [82] K. Smitha, A. Anitha, T. Furuike, H. Tamura, S.V. Nair, R. Jayakumar, Colloid. Surface. B. 730 104 (2013) 245-253. 731 [83] D.P. Gnanadhas, M.B. Thomas, M. Elango, A.M. Raichur, D. Chakravortty, J. Antimicrob. 732 Chemoth. 68 (2013) 2576-2586. 733 [84] K. Smitha, N. Nisha, S. Maya, R. Biswas, R. Jayakumar, Int. J. Biol. Macromol. 74 (2015) 734 36-43. 735 [85] T. Kean, M. Thanou, Adv. Drug. Deliver. Rev. 62 (2010) 3-11. 736\nPage 33 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n33\n[86] W. Thein-Han, J. Saikhun, C. Pholpramoo, R. Misra, Y. Kitiyanant, Acta Biomater. 5 737 (2009) 3453-3466. 738 [87] N. Bhattarai, J. Gunn, M. Zhang, Adv. Drug. Deliver. Rev. 62 (2010) 83-99. 739 [88] Y. Luo, T.T. Wang, Z. Teng, P. Chen, J. Sun, Q. Wang, Food Chem. 139 (2013) 224-230. 740 [89] M.A. Rather, R. Sharma, S. Gupta, S. Ferosekhan, V. Ramya, S.B. Jadhao, PloS One 8 741 (2013) 1-10. 742 [90] K.A. Janes, M.P. Fresneau, A. Marazuela, A. Fabra, M.a.J. Alonso, J. Control. Release 73 743 (2001) 255-267. 744 [91] S. Mitra, U. Gaur, P. Ghosh, A. Maitra, J. Control. Release 74 (2001) 317-323. 745 [92] A.M. De Campos, A. Sánchez, M.a.J. Alonso, Int. J. Pharm. 224 (2001) 159-168. 746 [93] T. Banerjee, S. Mitra, A.K. Singh, R.K. Sharma, A. Maitra, Int. J. Pharm. 243 (2002) 93-747 105. 748 [94] L. Qi, Z. Xu, X. Jiang, C. Hu, X. Zou, Carbohydr. Res. 339 (2004) 2693-2700. 749 [95] Q. Gan, T. Wang, C. Cochrane, P. McCarron, Colloid. Surface. B. 44 (2005) 65-73. 750 [96] H. Katas, H.O. Alpar, J. Control. Release 115 (2006) 216-225. 751 [97] K.H. Min, K. Park, Y.-S. Kim, S.M. Bae, S. Lee, H.G. Jo, R.-W. Park, I.-S. Kim, S.Y. 752 Jeong, K. Kim, J. Control. Release 127 (2008) 208-218. 753 [98] S.W. Ali, S. Rajendran, M. Joshi, Carbohydr. Polym. 83 (2011) 438-446. 754 [99] J.M.d. Lima, R.R. Sarmento, J.R.d. Souza, F.A. Brayner, A.P.S. Feitosa, R. Padilha, L.C. 755 Alves, I.J. Porto, R.F.B.D. Batista, J.E.d. Oliveira, BioMed Res. Int. 2015 (2015) 1-6. 756 [100] S.A. Agnihotri, N.N. Mallikarjuna, T.M. Aminabhavi, J. Control. Release. 100 (2004) 5-757 28. 758\nPage 34 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n34\n[101] X.-H. Wei, Y.-P. Niu, Y.-Y. Xu, Y.-Z. Du, F.-Q. Hu, H. Yuan, J. Bioact. Compat. Polym. 759 25 (2010) 319-335. 760 [102] A. López-Cruz, C. Barrera, V.L. Calero-DdelC, C. Rinaldi, J. Mater. Chem. 19 (2009) 761 6870-6876. 762 [103] K.H. Bae, M. Park, M.J. Do, N. Lee, J.H. Ryu, G.W. Kim, C. Kim, T.G. Park, T. Hyeon, 763 ACS Nano 6 (2012) 5266-5273. 764 [104] X. Liu, H. Huang, G. Liu, W. Zhou, Y. Chen, Q. Jin, J. Ji, Nanosc. 5 (2013) 3982-3991. 765 [105] Y.-S. Lin, M.-F. Wu, Y. Takamori, Y. Okamoto, S. Minami, J. Exp. Nanosci. 9 (2014) 766 860-870. 767 [106] C. Lu, M.K. Park, C. Lu, Y.H. Lee, K.Y. Chai, J. Mater. Chem. B. 3 (2015) 3730-3737. 768 [107] W. Wang, S.-X. Wang, H.-S. Guan, Mar. Drugs 10 (2012) 2795-2816. 769 [108] S. Mohanty, S. Mishra, P. Jena, B. Jacob, B. Sarkar, A. Sonawane, Nanomed-Nanotechnol. 770 8 (2012) 916-924. 771 [109] R. Allaker, J. Dent. Res. 89 (2010) 1175-1186. 772 [110] A.J. Kora, R. Sashidhar, J. Arunachalam, Carbohydr. Polym. 82 (2010) 670-679. 773 [111] M.K. Shukla, R.P. Singh, C. Reddy, B. Jha, Bioresource Technol. 107 (2012) 295-300. 774 [112] V. Venkatpurwar, V. Pokharkar, Mater. Lett. 65 (2011) 999-1002. 775 [113] W.H. De Jong, P.J. Borm, Int. J. Nanomed. 3 (2008) 133-149. 776 [114] A.E. De Salamanca, Y. Diebold, M. Calonge, C. García-Vazquez, S. Callejo, A. Vila, M.J. 777 Alonso, Invest. Ophth.Vis. Sci. 47 (2006) 1416-1425. 778 [115] M.d.l. Fuente, M. Raviña, P. Paolicelli, A. Sanchez, B. Seijo, M.J. Alonso, Adv. Drug 779 Deliver. Rev. 62 (2010) 100-117. 780 [116] S.-J. Wu, T.-M. Don, C.-W. Lin, F.-L. Mi, Mar. Drugs, 12 (2014) 5677-5697. 781\nPage 35 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n35\n[117] J.-o. You, Y.-c. Liu, C.-A. Peng, Int. J. Nanomed. 1 (2006) 173-180. 782 [118] A. Bozkir, O.M. Saka, Drug Deliv. 11 (2004) 107-112. 783 [119] D.W. Lee, K.-S. Yun, H.-S. Ban, W. Choe, S.K. Lee, K.Y. Lee, J. Control. Release 139 784 (2009) 146-152. 785 [120] H.K. Noh, S.W. Lee, J.-M. Kim, J.-E. Oh, K.-H. Kim, C.-P. Chung, S.-C. Choi, W.H. 786 Park, B.-M. Min, Biomaterials 27 (2006) 3934-3944. 787 [121] K. Shalumon, N. Binulal, N. Selvamurugan, S. Nair, D. Menon, T. Furuike, H. Tamura, R. 788 Jayakumar, Carbohydr. Polym. 77 (2009) 863-869. 789 [122] M. Peter, N. Ganesh, N. Selvamurugan, S. Nair, T. Furuike, H. Tamura, R. Jayakumar, 790 Carbohydr. Polym. 80 (2010) 687-694. 791 [123] Y.-I. Jeong, S.-G. Jin, I.-Y. Kim, J. Pei, M. Wen, T.-Y. Jung, K.-S. Moon, S. Jung, 792 Colloid. Surface. B. 79 (2010) 149-155. 793 [124] F. Li, J. Li, X. Wen, S. Zhou, X. Tong, P. Su, H. Li, D. Shi, Mater. Sci. Eng. C 29 (2009) 794 2392-2397. 795 [125] M. Rai, A. Yadav, A. Gade, Biotechnol. Adv. 27 (2009) 76-83. 796 [126] Z. Chen, X. Mo, C. He, H. Wang, Carbohydr. Polym. 72 (2008) 410-418. 797 [127] F. Teles, L. Fonseca, Mate. Sci. Eng. C. 28 (2008) 1530-1543. 798 [128] X.-J. Huang, D. Ge, Z.-K. Xu, Eur. Polym. J. 43 (2007) 3710-3718. 799 [129] S. Wang, Y. Tan, D. Zhao, G. Liu, Biosens. Bioelectron. 23 (2008) 1781-1787. 800 [130] N. Chauhan, J. Narang, C. Pundir, Int. J. Biol. Macromol. 51 (2012) 879-886. 801 [131] M.R. Gandhi, N. Viswanathan, S. Meenakshi, Int. J. Biol. Macromol. 47 (2010) 146-154. 802 [132] S. Fierro, M. del Pilar Sanchez-Saavedra, C. Copalcua, Bioresource Technol. 99 (2008) 803 1274-1279. 804\nPage 36 of 45\nAc\nce\npt ed\nM an\nus cr\nip\nt\n36\n[133] I. Donati, E. Marsich, A. Travan, S. Paoletti, in, US 2011/ 0129536 A1, 2009. 805 [134] I. Donati, E. Marsich, A. Travan, S. Paoletti, in, US 2011/0123589 A1, 2009. 806\n807\nFigures legends 808\nFig. 1. Various types of sulfated polysaccharides and their applications in 809 nanobiotechnology. 810\nFig. 2. Chemical structure of fucoidans, alginate, kappa (κ) carrageenan, iota (ι) 811 carrageenan, lambda (λ) carrageenan and agarose. 812\nFig. 3. Chemical structure of porphyran, ulvan, chitin, chitosan and acetylated fucoidan 813 nanoparticles. 814\nFig. 4. (A) Schematic representation showing porphyran capped gold nanoparticles. (B) 815 Schematic diagram of the functional structure of chitosan nanoparticles formed 816 during ionic gelation process. 817\nFig. 5. Procedures for marine polysaccharides-based nanomaterials and their applications 818\nFig. 6. (A) Schematic diagram of the preparation of berberine (Ber)-loaded 819 chitosan/fucoidan-taurine nanoparticles. (B) Schematic illustration of chitosan-820 alginate core-shell nanoparticles prepared by reverse microemulsion template. 821\n822\n823 824 825 826 827 828 829\nPage 37 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n37\n830 831 832 833 834 835 836\n837 838 839\nPage 38 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n38\nFig. 1 840 841 842 843 844 845 846 847 848 849\n850 851 Fig. 2 852 853 854\nPage 39 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n39\n855 856 857 858 859 860 861 862 863 864\n865 Fig. 3 866 867 868 869\nPage 40 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n40\n870 871 872 873 874 875 876\n877 878 Fig. 4 879 880 881 882\nPage 41 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n41\n883 884 885 886\nPage 42 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n42\n887 Fig. 5 888\nPage 43 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n43\n889\n890 Fig. 6 891\nPage 44 of 45\nAc ce\npt\n44\nMauran Bacteria Drug delivery Raveendran et al. [1] 894 895 896 897 Research Highlights 898 Marine polysaccharides-based nanomaterials are good candidates for biomedical fields 899 Marine polysaccharides are stable, biocompatible, biodegradable and non-toxic. 900 Marine algae are the most abundant source of polysaccharides 901 Chitin and chitosan derivatives are considerably versatile and promising biomaterials 902\nPage 45 of 45\nAc ce\npt ed\nM an\nus cr\nip t\n45\n903 904 Graphical Abstract 905 906 907\n908 909"
    } ],
    "references" : [ {
      "title" : "614 Carbohydr",
      "author" : [ "S. Raveendran", "B. Dhandayuthapani", "Y. Nagaoka", "Y. Yoshida", "T. Maekawa", "D.S. Kumar" ],
      "venue" : "Polym. 92 ",
      "citeRegEx" : "1",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "G",
      "author" : [ "K. Senni", "J. Pereira", "F. Gueniche", "C. Delbarre-Ladrat", "C. Sinquin", "J. Ratiskol" ],
      "venue" : "Godeau, A.- 616 M. Fischer, D. Helley, S. Colliec-Jouault, Mar. Drugs, 9 ",
      "citeRegEx" : "2",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Mar",
      "author" : [ "P. Laurienzo" ],
      "venue" : "Drugs, 8 ",
      "citeRegEx" : "3",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Nanomed-Nanotechnol",
      "author" : [ "S. Raveendran", "Y. Yoshida", "T. Maekawa", "D.S. Kumar" ],
      "venue" : "9 ",
      "citeRegEx" : "4",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Carbohydr",
      "author" : [ "R. Jayakumar", "D. Menon", "K. Manzoor", "S. Nair", "H. Tamura" ],
      "venue" : "Polym. 82 ",
      "citeRegEx" : "5",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Biotechnol",
      "author" : [ "R. Jayakumar", "M. Prabaharan", "S. Nair", "H. Tamura" ],
      "venue" : "Adv. 28 ",
      "citeRegEx" : "6",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "J",
      "author" : [ "L. Costa", "G. Fidelis", "S. Cordeiro", "R. Oliveira", "D. Sabry", "R. Câmara", "L. Nobre", "M. Costa" ],
      "venue" : "624 Almeida-Lima, E. Farias, Biomed. Pharmacother. 64 ",
      "citeRegEx" : "7",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Trends Glycosci",
      "author" : [ "T. Toida", "C. Amornrut", "R.J. Linhardt" ],
      "venue" : "Glyc. 15 ",
      "citeRegEx" : "8",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "J",
      "author" : [ "X. Wu", "D. Chen", "W. Indian Med" ],
      "venue" : "55 ",
      "citeRegEx" : "9",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Cancer Res",
      "author" : [ "C.R. Parish", "C. Freeman", "K.J. Brown", "D.J. Francis", "W.B. Cowden" ],
      "venue" : "59 ",
      "citeRegEx" : "11",
      "shortCiteRegEx" : null,
      "year" : 1999
    }, {
      "title" : "Antivir",
      "author" : [ "M. Luscher-Mattli" ],
      "venue" : "Chem. Chemoth. 11 ",
      "citeRegEx" : "12",
      "shortCiteRegEx" : null,
      "year" : 2000
    }, {
      "title" : "Trends Biotechnol",
      "author" : [ "D. Renn" ],
      "venue" : "15 ",
      "citeRegEx" : "13",
      "shortCiteRegEx" : null,
      "year" : 1997
    }, {
      "title" : "A",
      "author" : [ "M. Lahaye" ],
      "venue" : "Robic, Biomacromolecules 8 ",
      "citeRegEx" : "15",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Prog",
      "author" : [ "C. Pillai", "W. Paul", "C.P. Sharma" ],
      "venue" : "Polym. Sci. 34 ",
      "citeRegEx" : "16",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "J",
      "author" : [ "H. Ehrlich", "E. Steck", "M. Ilan", "M. Maldonado", "G. Muricy", "G. Bavestrello", "Z. Kljajic" ],
      "venue" : "637 Carballo, S. Schiaparelli, A. Ereskovsky, Int. J. Biol. Macromol. 47 ",
      "citeRegEx" : "17",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Food Hydrocolloid",
      "author" : [ "W. Xia", "P. Liu", "J. Zhang", "J. Chen" ],
      "venue" : "25 ",
      "citeRegEx" : "18",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Food Chem",
      "author" : [ "S.-B. Lin", "Y.-C. Lin", "H.-H. Chen" ],
      "venue" : "116 ",
      "citeRegEx" : "19",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Food Res",
      "author" : [ "X. Zhao", "W. Xia" ],
      "venue" : "Dev. 27 ",
      "citeRegEx" : "20",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "S",
      "author" : [ "K. Madhumathi", "N. Binulal", "H. Nagahama", "H. Tamura", "K. Shalumon", "N. Selvamurugan" ],
      "venue" : "642 Nair, R. Jayakumar, Int. J. Biol. Macromol. 44 ",
      "citeRegEx" : "21",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "R",
      "author" : [ "K. Madhumathi", "P.S. Kumar", "S. Abhilash", "V. Sreeja", "H. Tamura", "K. Manzoor", "S. Nair" ],
      "venue" : "644 Jayakumar, J. Mater. Sci-Mater. M. 21 ",
      "citeRegEx" : "22",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Int",
      "author" : [ "R. Jayakumar", "N. Nwe", "S. Tokura", "H. Tamura" ],
      "venue" : "J. Biol. Macromol. 40 ",
      "citeRegEx" : "23",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Food Sci",
      "author" : [ "W. Xia", "J. Chinese Ins" ],
      "venue" : "Technol. 3 ",
      "citeRegEx" : "24",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "Nutr",
      "author" : [ "F.-H. Liao", "M.-J. Shieh", "N.-C. Chang", "Y.-W. Chien" ],
      "venue" : "Res. 27 ",
      "citeRegEx" : "25",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "In: Se-Kwon Kim (Eds)",
      "author" : [ "P. Manivasagan", "S.-K. Kim" ],
      "venue" : "Adv. Food Nutr. Res. Burlington: 649 Academic Press, 72 ",
      "citeRegEx" : "26",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Bioresource Technol",
      "author" : [ "Z. Chi", "C. Su", "W. Lu" ],
      "venue" : "98 ",
      "citeRegEx" : "27",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "652 Int",
      "author" : [ "P. Manivasagan", "P. Sivasankar", "J. Venkatesan", "K. Senthilkumar", "K. Sivakumar", "S.-K. Kim" ],
      "venue" : "J. Biol. Macromol. 59 ",
      "citeRegEx" : "28",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Life Sci",
      "author" : [ "C. Sun", "J.-W. Wang", "L. Fang", "X.-D. Gao", "R.-X. Tan" ],
      "venue" : "75 ",
      "citeRegEx" : "29",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "Bioresource Technol",
      "author" : [ "A. Mishra", "B. Jha" ],
      "venue" : "100 ",
      "citeRegEx" : "30",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Carbohydr",
      "author" : [ "M. Zhang", "L. Zhang", "P.C.K. Cheung", "V.E.C. Ooi" ],
      "venue" : "Polym. 56 ",
      "citeRegEx" : "31",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "Int",
      "author" : [ "P. Manivasagan", "K.-H. Kang", "D.G. Kim", "S.-K. Kim" ],
      "venue" : "J. Biol. Macromol. 77 ",
      "citeRegEx" : "32",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Sci",
      "author" : [ "J.W. Lee", "J.H. Park", "J.R. Robinson", "J. Pharm" ],
      "venue" : "89 ",
      "citeRegEx" : "33",
      "shortCiteRegEx" : null,
      "year" : 2000
    }, {
      "title" : "Int",
      "author" : [ "V. Sinha", "R. Kumria" ],
      "venue" : "J. Pharm. 224 ",
      "citeRegEx" : "34",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "Carbohydr",
      "author" : [ "T.F. Vandamme", "A. Lenourry", "C. Charrueau", "J. Chaumeil" ],
      "venue" : "Polym. 48 ",
      "citeRegEx" : "35",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "Eur",
      "author" : [ "C. Lemarchand", "R. Gref", "P. Couvreur" ],
      "venue" : "J. Pharm. Biopharm. 58 ",
      "citeRegEx" : "36",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "Life Sci",
      "author" : [ "K.-J. Kim", "O.-H. Lee", "B.-Y. Lee" ],
      "venue" : "86 ",
      "citeRegEx" : "37",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "B",
      "author" : [ "O. Berteau" ],
      "venue" : "Mulloy, Glycobiology 13 ",
      "citeRegEx" : "39",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "Graph",
      "author" : [ "C.F. Becker", "J.A. Guimarães", "P.A. Mourão", "H. Verli", "J. Mol" ],
      "venue" : "Model. 26 ",
      "citeRegEx" : "40",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Int",
      "author" : [ "K. Hayashi", "T. Nakano", "M. Hashimoto", "K. Kanekiyo", "T. Hayashi" ],
      "venue" : "Immunopharmacol. 8 670 ",
      "citeRegEx" : "41",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "672 N",
      "author" : [ "A. Cumashi", "N.A. Ushakova", "M.E. Preobrazhenskaya", "A. D'Incecco", "A. Piccoli", "L. Totani" ],
      "venue" : "Tinari, G.E. Morozevich, A.E. Berman, M.I. Bilan, Glycobiology 17 ",
      "citeRegEx" : "42",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Int",
      "author" : [ "J. Wang", "Q. Zhang", "Z. Zhang", "Z. Li" ],
      "venue" : "J. Biol. Macromol. 42 ",
      "citeRegEx" : "43",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "R",
      "author" : [ "B. Li", "F. Lu", "X. Wei" ],
      "venue" : "Zhao, Molecules 13 ",
      "citeRegEx" : "44",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "676 Eur",
      "author" : [ "M. Lira", "N. Santos-Magalhães", "V. Nicolas", "V. Marsaud", "M. Silva", "G. Ponchel", "C. Vauthier" ],
      "venue" : "J. Pharm. Biopharm. 79 ",
      "citeRegEx" : "45",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Am",
      "author" : [ "K. Lirdprapamongkol", "W. Warisnoicharoen", "S. Soisuwan", "J. Svasti" ],
      "venue" : "J. Appl. Sci. 7 678 ",
      "citeRegEx" : "46",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Mater",
      "author" : [ "T.C.-Y. Leung", "C.K. Wong", "Y. Xie" ],
      "venue" : "Chem. Phys. 121 ",
      "citeRegEx" : "47",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Mar",
      "author" : [ "R. Kimura", "T. Rokkaku", "S. Takeda", "M. Senba", "N. Mori" ],
      "venue" : "Drugs 11 ",
      "citeRegEx" : "48",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Carbohydr",
      "author" : [ "K.W. Lee", "D. Jeong", "K. Na" ],
      "venue" : "Polym. 94 ",
      "citeRegEx" : "49",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Sci",
      "author" : [ "M. Rajaonarivony", "C. Vauthier", "G. Couarraze", "F. Puisieux", "P. Couvreur", "J. Pharm" ],
      "venue" : "82 683 ",
      "citeRegEx" : "50",
      "shortCiteRegEx" : null,
      "year" : 1993
    }, {
      "title" : "Nanotechno",
      "author" : [ "B. Sarmento", "A. Ribeiro", "F. Veiga", "D. Ferreira", "R. Neufeld", "J. Nanosci" ],
      "venue" : "7 685 ",
      "citeRegEx" : "51",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Nanomed-Nanotechnol",
      "author" : [ "Z. Ahmad", "S. Sharma", "G.K. Khuller" ],
      "venue" : "3 ",
      "citeRegEx" : "52",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Radiat",
      "author" : [ "N.T. Anh", "D. Van Phu", "N.N. Duy", "B.D. Du", "N.Q. Hien" ],
      "venue" : "Phys. Chem. 79 ",
      "citeRegEx" : "53",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Acta Mater",
      "author" : [ "J. Yang", "J. Pan" ],
      "venue" : "60 ",
      "citeRegEx" : "54",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Z",
      "author" : [ "C. Zhang", "W. Wang", "T. Liu", "Y. Wu", "H. Guo", "P. Wang", "Q. Tian", "Y. Wang" ],
      "venue" : "Yuan, 691 Biomaterials 33 ",
      "citeRegEx" : "55",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Int",
      "author" : [ "H. Guo", "Q. Lai", "W. Wang", "Y. Wu", "C. Zhang", "Y. Liu", "Z. Yuan" ],
      "venue" : "J. Pharm. 451 ",
      "citeRegEx" : "56",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Indian J",
      "author" : [ "R. Pandey", "G. Khuller" ],
      "venue" : "Exp. Biol. 44 ",
      "citeRegEx" : "57",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Int",
      "author" : [ "Z. Ahmad", "R. Pandey", "S. Sharma", "G.K. Khuller" ],
      "venue" : "J. Antimicrob. Ag. 27 ",
      "citeRegEx" : "58",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Int",
      "author" : [ "Y. Luo", "Q. Wang" ],
      "venue" : "J. Biol. Macromol. 64 ",
      "citeRegEx" : "59",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Sci",
      "author" : [ "Y.A. Shchipunov", "J. Colloid Interf" ],
      "venue" : "268 ",
      "citeRegEx" : "60",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "T",
      "author" : [ "A.L. Daniel-da-Silva" ],
      "venue" : "Trindade, B.J. Goodfellow, B.F. Costa, R.N. Correia, A.M. Gil, 699 Biomacromolecules 8 ",
      "citeRegEx" : "61",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Invest",
      "author" : [ "J. Stiles", "L. Guptill-Yoran", "G.E. Moore", "R.M. Pogranichniy" ],
      "venue" : "Ophth. Vis. Sci. 49 703 ",
      "citeRegEx" : "63",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "J",
      "author" : [ "A. Grenha", "M.E. Gomes", "M. Rodrigues", "V.E. Santo", "J.F. Mano", "N.M. Neves", "R.L. Reis" ],
      "venue" : "705 Biomed. Mater. Res. A. 92 ",
      "citeRegEx" : "64",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Carbohydr",
      "author" : [ "H. Hezaveh", "I.I. Muhamad" ],
      "venue" : "Polym. 89 ",
      "citeRegEx" : "66",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Carbohydr",
      "author" : [ "A.M. Salgueiro", "A.L. Daniel-da-Silva", "S. Fateixa", "T. Trindade" ],
      "venue" : "Polym. 91 709 ",
      "citeRegEx" : "67",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Sci",
      "author" : [ "K. Datta", "B. Srinivasan", "H. Balaram", "M. Eswaramoorthy", "J. Chem" ],
      "venue" : "120 ",
      "citeRegEx" : "68",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "712 Appl",
      "author" : [ "V. Kattumuri", "M. Chandrasekhar", "S. Guha", "K. Raghuraman", "K.V. Katti", "K. Ghosh", "R. Patel" ],
      "venue" : "Phys. Lett. 88 ",
      "citeRegEx" : "69",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Phycol",
      "author" : [ "D. Sahoo", "P. Baweja", "N. Kushwah", "J. Appl" ],
      "venue" : "18 ",
      "citeRegEx" : "70",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Life Sci",
      "author" : [ "M.-J. Kwon", "T.-J. Nam" ],
      "venue" : "79 ",
      "citeRegEx" : "71",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Int",
      "author" : [ "V. Venkatpurwar", "A. Shiras", "V. Pokharkar" ],
      "venue" : "J. Pharm. 409 ",
      "citeRegEx" : "72",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Toxicol",
      "author" : [ "V. Venkatpurwar", "V. Mali", "S. Bodhankar", "V. Pokharkar" ],
      "venue" : "Environ. Chem. 94 ",
      "citeRegEx" : "73",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "719 Carbohydr",
      "author" : [ "G. Toskas", "R.-D. Hund", "E. Laourine", "C. Cherif", "V. Smyrniotopoulos", "V. Roussis" ],
      "venue" : "Poly. 84 ",
      "citeRegEx" : "74",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Polym",
      "author" : [ "S. Kikionis", "E. Ioannou", "G. Toskas", "V. Roussis", "J. Appl" ],
      "venue" : "Sci. 132 ",
      "citeRegEx" : "75",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Carbohydr",
      "author" : [ "S. Raveendran", "A.C. Poulose", "Y. Yoshida", "T. Maekawa", "D.S. Kumar" ],
      "venue" : "Polym. 91 722 ",
      "citeRegEx" : "76",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Bioresource Technol",
      "author" : [ "S. Wibowo", "G. Velazquez", "V. Savant", "J.A. Torres" ],
      "venue" : "96 ",
      "citeRegEx" : "77",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Release",
      "author" : [ "R. Hejazi", "M. Amiji", "J. Control" ],
      "venue" : "89 ",
      "citeRegEx" : "78",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "Carbohydr",
      "author" : [ "P.R. Chang", "R. Jian", "J. Yu", "X. Ma" ],
      "venue" : "Polym. 80 ",
      "citeRegEx" : "79",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Biol",
      "author" : [ "Y. Song", "H. Onishi", "T. Nagai" ],
      "venue" : "Pharm. Bull. 16 ",
      "citeRegEx" : "80",
      "shortCiteRegEx" : null,
      "year" : 1993
    }, {
      "title" : "R",
      "author" : [ "A. Dev", "J.C. Mohan", "V. Sreeja", "H. Tamura", "G. Patzke", "F. Hussain", "S. Weyeneth", "S. Nair" ],
      "venue" : "728 Jayakumar, Carbohydr. Polym. 79 ",
      "citeRegEx" : "81",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Colloid",
      "author" : [ "K. Smitha", "A. Anitha", "T. Furuike", "H. Tamura", "S.V. Nair", "R. Jayakumar" ],
      "venue" : "Surface. B. 730 104 ",
      "citeRegEx" : "82",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "732 Chemoth",
      "author" : [ "D.P. Gnanadhas", "M.B. Thomas", "M. Elango", "A.M. Raichur", "D. Chakravortty", "J. Antimicrob" ],
      "venue" : "68 ",
      "citeRegEx" : "83",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Int",
      "author" : [ "K. Smitha", "N. Nisha", "S. Maya", "R. Biswas", "R. Jayakumar" ],
      "venue" : "J. Biol. Macromol. 74 ",
      "citeRegEx" : "84",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Adv",
      "author" : [ "T. Kean", "M. Thanou" ],
      "venue" : "Drug. Deliver. Rev. 62 ",
      "citeRegEx" : "85",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Acta Biomater",
      "author" : [ "W. Thein-Han", "J. Saikhun", "C. Pholpramoo", "R. Misra", "Y. Kitiyanant" ],
      "venue" : "5 737 ",
      "citeRegEx" : "86",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Adv",
      "author" : [ "N. Bhattarai", "J. Gunn", "M. Zhang" ],
      "venue" : "Drug. Deliver. Rev. 62 ",
      "citeRegEx" : "87",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Food Chem",
      "author" : [ "Y. Luo", "T.T. Wang", "Z. Teng", "P. Chen", "J. Sun", "Q. Wang" ],
      "venue" : "139 ",
      "citeRegEx" : "88",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "V",
      "author" : [ "M.A. Rather", "R. Sharma", "S. Gupta", "S. Ferosekhan" ],
      "venue" : "Ramya, S.B. Jadhao, PloS One 8 741 ",
      "citeRegEx" : "89",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "A",
      "author" : [ "K.A. Janes", "M.P. Fresneau", "A. Marazuela" ],
      "venue" : "Fabra, M.a.J. Alonso, J. Control. Release 73 743 ",
      "citeRegEx" : "90",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "J",
      "author" : [ "S. Mitra", "U. Gaur", "P. Ghosh", "A. Maitra" ],
      "venue" : "Control. Release 74 ",
      "citeRegEx" : "91",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "A",
      "author" : [ "A.M. De Campos" ],
      "venue" : "Sánchez, M.a.J. Alonso, Int. J. Pharm. 224 ",
      "citeRegEx" : "92",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "Int",
      "author" : [ "T. Banerjee", "S. Mitra", "A.K. Singh", "R.K. Sharma", "A. Maitra" ],
      "venue" : "J. Pharm. 243 ",
      "citeRegEx" : "93",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "Carbohydr",
      "author" : [ "L. Qi", "Z. Xu", "X. Jiang", "C. Hu", "X. Zou" ],
      "venue" : "Res. 339 ",
      "citeRegEx" : "94",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "Colloid",
      "author" : [ "Q. Gan", "T. Wang", "C. Cochrane", "P. McCarron" ],
      "venue" : "Surface. B. 44 ",
      "citeRegEx" : "95",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "J",
      "author" : [ "H. Katas", "H.O. Alpar" ],
      "venue" : "Control. Release 115 ",
      "citeRegEx" : "96",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "S",
      "author" : [ "K.H. Min", "K. Park", "Y.-S. Kim", "S.M. Bae" ],
      "venue" : "Lee, H.G. Jo, R.-W. Park, I.-S. Kim, S.Y. 752 Jeong, K. Kim, J. Control. Release 127 ",
      "citeRegEx" : "97",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Carbohydr",
      "author" : [ "S.W. Ali", "S. Rajendran", "M. Joshi" ],
      "venue" : "Polym. 83 ",
      "citeRegEx" : "98",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Release",
      "author" : [ "S.A. Agnihotri", "N.N. Mallikarjuna", "T.M. Aminabhavi", "J. Control" ],
      "venue" : "100 ",
      "citeRegEx" : "100",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "Compat",
      "author" : [ "X.-H. Wei", "Y.-P. Niu", "Y.-Y. Xu", "Y.-Z. Du", "F.-Q. Hu", "H. Yuan", "J. Bioact" ],
      "venue" : "Polym. 759 25 ",
      "citeRegEx" : "101",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Chem",
      "author" : [ "A. López-Cruz", "C. Barrera", "V.L. Calero-DdelC", "C. Rinaldi", "J. Mater" ],
      "venue" : "19 ",
      "citeRegEx" : "102",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "T",
      "author" : [ "K.H. Bae", "M. Park", "M.J. Do", "N. Lee", "J.H. Ryu", "G.W. Kim", "C. Kim", "T.G. Park" ],
      "venue" : "Hyeon, 763 ACS Nano 6 ",
      "citeRegEx" : "103",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Nanosc",
      "author" : [ "X. Liu", "H. Huang", "G. Liu", "W. Zhou", "Y. Chen", "Q. Jin", "J. Ji" ],
      "venue" : "5 ",
      "citeRegEx" : "104",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Nanosci",
      "author" : [ "Y.-S. Lin", "M.-F. Wu", "Y. Takamori", "Y. Okamoto", "S. Minami", "J. Exp" ],
      "venue" : "9 ",
      "citeRegEx" : "105",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Chem",
      "author" : [ "C. Lu", "M.K. Park", "C. Lu", "Y.H. Lee", "K.Y. Chai", "J. Mater" ],
      "venue" : "B. 3 ",
      "citeRegEx" : "106",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Mar",
      "author" : [ "W. Wang", "S.-X. Wang", "H.-S. Guan" ],
      "venue" : "Drugs 10 ",
      "citeRegEx" : "107",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Nanomed-Nanotechnol",
      "author" : [ "S. Mohanty", "S. Mishra", "P. Jena", "B. Jacob", "B. Sarkar", "A. Sonawane" ],
      "venue" : "770 8 ",
      "citeRegEx" : "108",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Res",
      "author" : [ "R. Allaker", "J. Dent" ],
      "venue" : "89 ",
      "citeRegEx" : "109",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Carbohydr",
      "author" : [ "A.J. Kora", "R. Sashidhar", "J. Arunachalam" ],
      "venue" : "Polym. 82 ",
      "citeRegEx" : "110",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Bioresource Technol",
      "author" : [ "M.K. Shukla", "R.P. Singh", "C. Reddy", "B. Jha" ],
      "venue" : "107 ",
      "citeRegEx" : "111",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Mater",
      "author" : [ "V. Venkatpurwar", "V. Pokharkar" ],
      "venue" : "Lett. 65 ",
      "citeRegEx" : "112",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Int",
      "author" : [ "W.H. De Jong", "P.J. Borm" ],
      "venue" : "J. Nanomed. 3 ",
      "citeRegEx" : "113",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "A",
      "author" : [ "A.E. De Salamanca", "Y. Diebold", "M. Calonge", "C. García-Vazquez", "S. Callejo" ],
      "venue" : "Vila, M.J. 777 Alonso, Invest. Ophth.Vis. Sci. 47 ",
      "citeRegEx" : "114",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Mar",
      "author" : [ "S.-J. Wu", "T.-M. Don", "C.-W. Lin", "F.-L. Mi" ],
      "venue" : "Drugs, 12 ",
      "citeRegEx" : "116",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Drug Deliv",
      "author" : [ "A. Bozkir", "O.M. Saka" ],
      "venue" : "11 ",
      "citeRegEx" : "118",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "J",
      "author" : [ "D.W. Lee", "K.-S. Yun", "H.-S. Ban", "W. Choe", "S.K. Lee", "K.Y. Lee" ],
      "venue" : "Control. Release 139 784 ",
      "citeRegEx" : "119",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "R",
      "author" : [ "K. Shalumon", "N. Binulal", "N. Selvamurugan", "S. Nair", "D. Menon", "T. Furuike", "H. Tamura" ],
      "venue" : "788 Jayakumar, Carbohydr. Polym. 77 ",
      "citeRegEx" : "121",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "790 Carbohydr",
      "author" : [ "M. Peter", "N. Ganesh", "N. Selvamurugan", "S. Nair", "T. Furuike", "H. Tamura", "R. Jayakumar" ],
      "venue" : "Polym. 80 ",
      "citeRegEx" : "122",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "792 Colloid",
      "author" : [ "Y.-I. Jeong", "S.-G. Jin", "I.-Y. Kim", "J. Pei", "M. Wen", "T.-Y. Jung", "K.-S. Moon", "S. Jung" ],
      "venue" : "Surface. B. 79 ",
      "citeRegEx" : "123",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Mater",
      "author" : [ "F. Li", "J. Li", "X. Wen", "S. Zhou", "X. Tong", "P. Su", "H. Li", "D. Shi" ],
      "venue" : "Sci. Eng. C 29 ",
      "citeRegEx" : "124",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Biotechnol",
      "author" : [ "M. Rai", "A. Yadav", "A. Gade" ],
      "venue" : "Adv. 27 ",
      "citeRegEx" : "125",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Carbohydr",
      "author" : [ "Z. Chen", "X. Mo", "C. He", "H. Wang" ],
      "venue" : "Polym. 72 ",
      "citeRegEx" : "126",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Mate",
      "author" : [ "F. Teles", "L. Fonseca" ],
      "venue" : "Sci. Eng. C. 28 ",
      "citeRegEx" : "127",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Eur",
      "author" : [ "X.-J. Huang", "D. Ge", "Z.-K. Xu" ],
      "venue" : "Polym. J. 43 ",
      "citeRegEx" : "128",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Biosens",
      "author" : [ "S. Wang", "Y. Tan", "D. Zhao", "G. Liu" ],
      "venue" : "Bioelectron. 23 ",
      "citeRegEx" : "129",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Int",
      "author" : [ "N. Chauhan", "J. Narang", "C. Pundir" ],
      "venue" : "J. Biol. Macromol. 51 ",
      "citeRegEx" : "130",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Int",
      "author" : [ "M.R. Gandhi", "N. Viswanathan", "S. Meenakshi" ],
      "venue" : "J. Biol. Macromol. 47 ",
      "citeRegEx" : "131",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "M",
      "author" : [ "S. Fierro" ],
      "venue" : "del Pilar Sanchez-Saavedra, C. Copalcua, Bioresource Technol. 99 ",
      "citeRegEx" : "132",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "in",
      "author" : [ "I. Donati", "E. Marsich", "A. Travan", "S. Paoletti" ],
      "venue" : "US 2011/ 0129536 A1",
      "citeRegEx" : "133",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "in",
      "author" : [ "I. Donati", "E. Marsich", "A. Travan", "S. Paoletti" ],
      "venue" : "US 2011/0123589 A1",
      "citeRegEx" : "134",
      "shortCiteRegEx" : null,
      "year" : 2009
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "Introduction 63 Marine polysaccharides have a great promise for applications in modern medicine and 64 nanobiotechnology and are well known in the biomedical engineering field for several 65 applications, namely gene delivery, drug delivery, tissue engineering, and wound dressing [1].",
      "startOffset" : 281,
      "endOffset" : 284
    }, {
      "referenceID" : 1,
      "context" : "Marine algae have been recognized as a rich source of sulfated 68 polysaccharides, including fucoidan, alginate, carrageenan, agarose, porphyran, and ulvan [2].",
      "startOffset" : 156,
      "endOffset" : 159
    }, {
      "referenceID" : 2,
      "context" : "Exopolysaccharides (EPS) produced by marine microorganisms are a complex 71 mixture of biopolymers mainly consisting of polysaccharides as well as nucleic acids, lipids, 72 proteins, and humic substances [3].",
      "startOffset" : 204,
      "endOffset" : 207
    }, {
      "referenceID" : 3,
      "context" : "Marine polysaccharide-based nanomaterials have attracted attention as one of the most 74 important research in the recent years, particularly, in biomedical and chemical research because 75 of their good biocompatibility, biodegradability, nontoxicity, low cost, and abundance [4].",
      "startOffset" : 277,
      "endOffset" : 280
    }, {
      "referenceID" : 4,
      "context" : "diseases, including cancer and bacterial pathogens and for tissue engineering, drug delivery, gene 79 delivery, and wound healing [5].",
      "startOffset" : 130,
      "endOffset" : 133
    }, {
      "referenceID" : 3,
      "context" : "In 87 nature, marine polysaccharides are derived from various resources such as marine algae, 88 crustaceans, and microorganisms [4].",
      "startOffset" : 129,
      "endOffset" : 132
    }, {
      "referenceID" : 6,
      "context" : "For decades, they have been used for various biological and 90 biomedical applications, namely anticoagulant [7], antioxidant [7], anti-inflammatory [8], 91 antiproliferative [7], antiviral [8], antitumor [9], antiparasitic [8], antiangiogenic [10], 92 antimetastatic [11], and immunomodulating [8] activities.",
      "startOffset" : 109,
      "endOffset" : 112
    }, {
      "referenceID" : 6,
      "context" : "For decades, they have been used for various biological and 90 biomedical applications, namely anticoagulant [7], antioxidant [7], anti-inflammatory [8], 91 antiproliferative [7], antiviral [8], antitumor [9], antiparasitic [8], antiangiogenic [10], 92 antimetastatic [11], and immunomodulating [8] activities.",
      "startOffset" : 126,
      "endOffset" : 129
    }, {
      "referenceID" : 7,
      "context" : "For decades, they have been used for various biological and 90 biomedical applications, namely anticoagulant [7], antioxidant [7], anti-inflammatory [8], 91 antiproliferative [7], antiviral [8], antitumor [9], antiparasitic [8], antiangiogenic [10], 92 antimetastatic [11], and immunomodulating [8] activities.",
      "startOffset" : 149,
      "endOffset" : 152
    }, {
      "referenceID" : 6,
      "context" : "For decades, they have been used for various biological and 90 biomedical applications, namely anticoagulant [7], antioxidant [7], anti-inflammatory [8], 91 antiproliferative [7], antiviral [8], antitumor [9], antiparasitic [8], antiangiogenic [10], 92 antimetastatic [11], and immunomodulating [8] activities.",
      "startOffset" : 175,
      "endOffset" : 178
    }, {
      "referenceID" : 7,
      "context" : "For decades, they have been used for various biological and 90 biomedical applications, namely anticoagulant [7], antioxidant [7], anti-inflammatory [8], 91 antiproliferative [7], antiviral [8], antitumor [9], antiparasitic [8], antiangiogenic [10], 92 antimetastatic [11], and immunomodulating [8] activities.",
      "startOffset" : 190,
      "endOffset" : 193
    }, {
      "referenceID" : 8,
      "context" : "For decades, they have been used for various biological and 90 biomedical applications, namely anticoagulant [7], antioxidant [7], anti-inflammatory [8], 91 antiproliferative [7], antiviral [8], antitumor [9], antiparasitic [8], antiangiogenic [10], 92 antimetastatic [11], and immunomodulating [8] activities.",
      "startOffset" : 205,
      "endOffset" : 208
    }, {
      "referenceID" : 7,
      "context" : "For decades, they have been used for various biological and 90 biomedical applications, namely anticoagulant [7], antioxidant [7], anti-inflammatory [8], 91 antiproliferative [7], antiviral [8], antitumor [9], antiparasitic [8], antiangiogenic [10], 92 antimetastatic [11], and immunomodulating [8] activities.",
      "startOffset" : 224,
      "endOffset" : 227
    }, {
      "referenceID" : 9,
      "context" : "For decades, they have been used for various biological and 90 biomedical applications, namely anticoagulant [7], antioxidant [7], anti-inflammatory [8], 91 antiproliferative [7], antiviral [8], antitumor [9], antiparasitic [8], antiangiogenic [10], 92 antimetastatic [11], and immunomodulating [8] activities.",
      "startOffset" : 268,
      "endOffset" : 272
    }, {
      "referenceID" : 7,
      "context" : "For decades, they have been used for various biological and 90 biomedical applications, namely anticoagulant [7], antioxidant [7], anti-inflammatory [8], 91 antiproliferative [7], antiviral [8], antitumor [9], antiparasitic [8], antiangiogenic [10], 92 antimetastatic [11], and immunomodulating [8] activities.",
      "startOffset" : 295,
      "endOffset" : 298
    }, {
      "referenceID" : 10,
      "context" : "The sulfated polysaccharides have 93 been of great interest in recent years because of their potential to produce novel bioactive 94 compounds [12].",
      "startOffset" : 143,
      "endOffset" : 147
    }, {
      "referenceID" : 11,
      "context" : "The sulfated polysaccharides 98 extracted from marine algae have received considerable attention in the nutraceutical, 99 cosmeceutical, and pharmaceutical fields [13].",
      "startOffset" : 163,
      "endOffset" : 167
    }, {
      "referenceID" : 4,
      "context" : "Chitin 107 Chitin is one of the most abundant natural polymers on earth and is found in the 108 exoskeletons of marine crustaceans and cell walls of marine fungi [5].",
      "startOffset" : 162,
      "endOffset" : 165
    }, {
      "referenceID" : 13,
      "context" : "This biopolymer is easily processed into nanoparticles, 111 nanofibers, microparticles, membranes, scaffolds, gels, beads, and sponge forms in the 112 biomedical field because of their excellent biocompatibility, high biodegradability and low 113 toxicity [16].",
      "startOffset" : 256,
      "endOffset" : 260
    }, {
      "referenceID" : 14,
      "context" : "These properties, find various biomedical applications such as targeted drug 114 delivery, gene delivery, wound dressing, and tissue engineering in the area of nanotechnology 115 [17].",
      "startOffset" : 179,
      "endOffset" : 183
    }, {
      "referenceID" : 15,
      "context" : "Recently, 119 CS is of a special interest for applications in the chemical, nutraceutical, and pharmaceutical 120 industries [18].",
      "startOffset" : 125,
      "endOffset" : 129
    }, {
      "referenceID" : 17,
      "context" : "CS and COSs have a great promise in recent years because 125 of their biomedical applications, namely antimicrobial activity [20], tissue engineering [21], 126 wound healing [22], drug delivery [23], antitumor effects [24], and hypocholesterolemic effects 127",
      "startOffset" : 125,
      "endOffset" : 129
    }, {
      "referenceID" : 18,
      "context" : "CS and COSs have a great promise in recent years because 125 of their biomedical applications, namely antimicrobial activity [20], tissue engineering [21], 126 wound healing [22], drug delivery [23], antitumor effects [24], and hypocholesterolemic effects 127",
      "startOffset" : 150,
      "endOffset" : 154
    }, {
      "referenceID" : 19,
      "context" : "CS and COSs have a great promise in recent years because 125 of their biomedical applications, namely antimicrobial activity [20], tissue engineering [21], 126 wound healing [22], drug delivery [23], antitumor effects [24], and hypocholesterolemic effects 127",
      "startOffset" : 174,
      "endOffset" : 178
    }, {
      "referenceID" : 20,
      "context" : "CS and COSs have a great promise in recent years because 125 of their biomedical applications, namely antimicrobial activity [20], tissue engineering [21], 126 wound healing [22], drug delivery [23], antitumor effects [24], and hypocholesterolemic effects 127",
      "startOffset" : 194,
      "endOffset" : 198
    }, {
      "referenceID" : 21,
      "context" : "CS and COSs have a great promise in recent years because 125 of their biomedical applications, namely antimicrobial activity [20], tissue engineering [21], 126 wound healing [22], drug delivery [23], antitumor effects [24], and hypocholesterolemic effects 127",
      "startOffset" : 218,
      "endOffset" : 222
    }, {
      "referenceID" : 23,
      "context" : "Marine microorganisms 129 Marine microbial EPS are natural biopolymers primarily consisting of polysaccharides 130 produced by bacteria [26], cyanobacteria [27], actinobacteria [28], and fungi [29].",
      "startOffset" : 136,
      "endOffset" : 140
    }, {
      "referenceID" : 24,
      "context" : "Marine microorganisms 129 Marine microbial EPS are natural biopolymers primarily consisting of polysaccharides 130 produced by bacteria [26], cyanobacteria [27], actinobacteria [28], and fungi [29].",
      "startOffset" : 156,
      "endOffset" : 160
    }, {
      "referenceID" : 25,
      "context" : "Marine microorganisms 129 Marine microbial EPS are natural biopolymers primarily consisting of polysaccharides 130 produced by bacteria [26], cyanobacteria [27], actinobacteria [28], and fungi [29].",
      "startOffset" : 177,
      "endOffset" : 181
    }, {
      "referenceID" : 26,
      "context" : "Marine microorganisms 129 Marine microbial EPS are natural biopolymers primarily consisting of polysaccharides 130 produced by bacteria [26], cyanobacteria [27], actinobacteria [28], and fungi [29].",
      "startOffset" : 193,
      "endOffset" : 197
    }, {
      "referenceID" : 27,
      "context" : "Nowadays, 131 EPS have attracted increasing attention in pharmaceutical, cosmeceutical, and nutraceutical 132 industries as well as in wastewater treatment and detergent applications [30].",
      "startOffset" : 183,
      "endOffset" : 187
    }, {
      "referenceID" : 28,
      "context" : "Marine microbial 133 polysaccharides have been a growing interest for biological activities such as antiviral, anti134 inflammatory, and antitumor activates [31].",
      "startOffset" : 157,
      "endOffset" : 161
    }, {
      "referenceID" : 0,
      "context" : "[1] reported an extremophilic 135 bacterial polysaccharide, mauran (MR), for the first time as a novel biocompatible and stable 136 biomaterial to the world of nanotechnology, pharmaceutics and biomedical technology.",
      "startOffset" : 0,
      "endOffset" : 3
    }, {
      "referenceID" : 29,
      "context" : "[32] studied the production of polysaccharide-based bioflocculant for the 138 green synthesis of silver nanoparticles by Streptomyces sp.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 30,
      "context" : "safe, hydrophilic, biocompatible, and biodegradable [33].",
      "startOffset" : 52,
      "endOffset" : 56
    }, {
      "referenceID" : 34,
      "context" : "2) is a naturally occurring sulfated polysaccharide extracted from 154 marine brown seaweeds [37, 38].",
      "startOffset" : 93,
      "endOffset" : 101
    }, {
      "referenceID" : 35,
      "context" : "Similar fucan sulfates were obtained from marine invertebrates 155 [39].",
      "startOffset" : 67,
      "endOffset" : 71
    }, {
      "referenceID" : 36,
      "context" : "Recently, fucoidan 156 has been investigated because of its various biological properties such as anticoagulant [40], 157 antiviral [41], antiangiogenic, antitumor, anti-inflammatory, [42], antioxidant [43], 158 antiproliferative and immunomodulating properties [41].",
      "startOffset" : 112,
      "endOffset" : 116
    }, {
      "referenceID" : 37,
      "context" : "Recently, fucoidan 156 has been investigated because of its various biological properties such as anticoagulant [40], 157 antiviral [41], antiangiogenic, antitumor, anti-inflammatory, [42], antioxidant [43], 158 antiproliferative and immunomodulating properties [41].",
      "startOffset" : 132,
      "endOffset" : 136
    }, {
      "referenceID" : 38,
      "context" : "Recently, fucoidan 156 has been investigated because of its various biological properties such as anticoagulant [40], 157 antiviral [41], antiangiogenic, antitumor, anti-inflammatory, [42], antioxidant [43], 158 antiproliferative and immunomodulating properties [41].",
      "startOffset" : 184,
      "endOffset" : 188
    }, {
      "referenceID" : 39,
      "context" : "Recently, fucoidan 156 has been investigated because of its various biological properties such as anticoagulant [40], 157 antiviral [41], antiangiogenic, antitumor, anti-inflammatory, [42], antioxidant [43], 158 antiproliferative and immunomodulating properties [41].",
      "startOffset" : 202,
      "endOffset" : 206
    }, {
      "referenceID" : 37,
      "context" : "Recently, fucoidan 156 has been investigated because of its various biological properties such as anticoagulant [40], 157 antiviral [41], antiangiogenic, antitumor, anti-inflammatory, [42], antioxidant [43], 158 antiproliferative and immunomodulating properties [41].",
      "startOffset" : 262,
      "endOffset" : 266
    }, {
      "referenceID" : 40,
      "context" : "In the past few years, a large number of 159 researchers of novel bioactive compounds have taken special interest in fucoidans [44].",
      "startOffset" : 127,
      "endOffset" : 131
    }, {
      "referenceID" : 41,
      "context" : "[45] reported the synthesis and characterization of fucoidan-coated poly 163 (isobutylcyanoacrylate) nanoparticles.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 42,
      "context" : "Fucoidans were used for the green synthesis of gold nanoparticles [46].",
      "startOffset" : 66,
      "endOffset" : 70
    }, {
      "referenceID" : 43,
      "context" : "[47] reported the biosynthesis of silver nanoparticles using 171 carboxymethylated curdlan or fucoidan as reducing and stabilizing agents.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 45,
      "context" : "The nanoparticles were characterized by their morphology 178 and drug release properties [49].",
      "startOffset" : 89,
      "endOffset" : 93
    }, {
      "referenceID" : 46,
      "context" : "2) is a natural polysaccharide extracted from brown seaweeds and has 181 been widely investigated and used for biomedical applications because of their excellent 182 biocompatibility, low cost, low toxicity, and mild gelation [50].",
      "startOffset" : 226,
      "endOffset" : 230
    }, {
      "referenceID" : 47,
      "context" : "Nowadays, a large number of 183 studies for alginate-based nanoparticles have raised greater interest in the medical field because 184 of their potential applications such as in insulin delivery [51] and antifungal and antitubercular 185 drugs [52].",
      "startOffset" : 195,
      "endOffset" : 199
    }, {
      "referenceID" : 48,
      "context" : "Nowadays, a large number of 183 studies for alginate-based nanoparticles have raised greater interest in the medical field because 184 of their potential applications such as in insulin delivery [51] and antifungal and antitubercular 185 drugs [52].",
      "startOffset" : 244,
      "endOffset" : 248
    }, {
      "referenceID" : 47,
      "context" : "[51] prepared insulin-loaded nanoparticles using alginate ionotropic pre187 gelation followed by CS polyelectrolyte complexation.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 49,
      "context" : "193 [53] reported an effective γ-irradiation method for the preparation of gold nanoparticles using 194 alginate, a natural polysaccharide, as a stabilizer.",
      "startOffset" : 4,
      "endOffset" : 8
    }, {
      "referenceID" : 50,
      "context" : "199 Yang and Pan [54] studied the hydrothermal synthesis of silver nanoparticles using 200 sodium alginate as a reducing and stabilizing agent.",
      "startOffset" : 17,
      "endOffset" : 21
    }, {
      "referenceID" : 51,
      "context" : "[55] studied DOX-loaded glycyrrhetinic acid-modified alginate nanoparticles 207 (ALG NPs) for liver tumor chemotherapy.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 52,
      "context" : "These results showed 213 that GA-ALG/DOX-ALG NPs may act as a therapeutic agents in liver cancer treatment [56].",
      "startOffset" : 107,
      "endOffset" : 111
    }, {
      "referenceID" : 53,
      "context" : "delivery systems offers a new perspective for the treatment of tuberculosis [57].",
      "startOffset" : 76,
      "endOffset" : 80
    }, {
      "referenceID" : 54,
      "context" : "219 [58] studied the pharmacokinetics and tissue distribution of free and alginate-encapsulated 220",
      "startOffset" : 4,
      "endOffset" : 8
    }, {
      "referenceID" : 55,
      "context" : "Among the three types of carrageenan, κ- and ι231 carrageenan have a high gelling efficiency, with the former being rigid and firm and the latter 232 being elastic and soft in nature [59].",
      "startOffset" : 183,
      "endOffset" : 187
    }, {
      "referenceID" : 56,
      "context" : "λ-Carrageenan is a non-gelling polysaccharide [60].",
      "startOffset" : 46,
      "endOffset" : 50
    }, {
      "referenceID" : 57,
      "context" : "[61] investigated the biosynthesis of magnetite nanoparticles using carrageenan.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 58,
      "context" : "[63] reported the inhibitory effect of λ238",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 58,
      "context" : "The IC50 of λ-carrageenan against FHV-1 was found to be 5 240 μg/mL [63].",
      "startOffset" : 68,
      "endOffset" : 72
    }, {
      "referenceID" : 59,
      "context" : "[64] developed a novel formation of carrageenan and CS nanoparticles as a 242",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 60,
      "context" : "Hezaveh and Muhamad [66] reported the 251 effect of metallic nanoparticles on gastrointestinal release from modified κ-carrageenan 252 hydrogels.",
      "startOffset" : 20,
      "endOffset" : 24
    }, {
      "referenceID" : 61,
      "context" : "[67] demonstrated the effect of 256 incorporating spherical and rod-shaped gold nanoparticles in the microstructure and 257 thermomechanical properties of κ-carrageenan hydrogels and in the release kinetics and 258 mechanism of methylene blue from κ-carrageenan nanocomposites.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 62,
      "context" : "Interestingly, the agarose 269 composite films can be quickly converted to carbon-metal composites by carbonizing the films 270 in nitrogen atmosphere [68].",
      "startOffset" : 151,
      "endOffset" : 155
    }, {
      "referenceID" : 63,
      "context" : "[69] reported the use of agarose-stabilized gold 271 nanoparticles for the detection of micromolar concentrations of DNA nucleosides using surface272 enhanced Raman spectroscopic detection.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 64,
      "context" : "3) is a naturally occurring sulfated polysaccharide extracted from 277 marine red seaweed, Porphyra vietnamensis [70].",
      "startOffset" : 113,
      "endOffset" : 117
    }, {
      "referenceID" : 65,
      "context" : "and antioxidant activities of porphyran [71].",
      "startOffset" : 40,
      "endOffset" : 44
    }, {
      "referenceID" : 66,
      "context" : "[72] reported the biosynthesis 284 of gold nanoparticles using a porphyran and subsequent loading of DOX.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 67,
      "context" : "[73] demonstrated that the toxicology profile comprises in vitro cytotoxic 288",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 12,
      "context" : "The potential applications of ulvan 297 have been investigated as an antioxidant, antitumor, anticoagulant, and immune modulator [15].",
      "startOffset" : 129,
      "endOffset" : 133
    }, {
      "referenceID" : 68,
      "context" : "[74] reported the spinnability of ulvan-rich, isolated polysaccharides from 304 marine green seaweed Ulva rigida that was used for the fabrication of nanofibers.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 69,
      "context" : "[75] prepared novel fibrous biocomposites of 308 ulvan using the electrospinning technique.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 70,
      "context" : "The pseudoplastic and thixotropic natures of mauran make it an ideal 317 molecule for material science applications [76].",
      "startOffset" : 116,
      "endOffset" : 120
    }, {
      "referenceID" : 0,
      "context" : "[1] reported the synthesis of 318 sulfated polysaccharide-based nanoparticles as a good biocompatible material for anticancer 319 activity, drug delivery and bioimaging.",
      "startOffset" : 0,
      "endOffset" : 3
    }, {
      "referenceID" : 71,
      "context" : "3) is also a biopolymer that is abundant in nature [77].",
      "startOffset" : 51,
      "endOffset" : 55
    }, {
      "referenceID" : 72,
      "context" : "Worldwide, several 323 million tons of chitin are generated annually as waste by the seafood industry [78].",
      "startOffset" : 102,
      "endOffset" : 106
    }, {
      "referenceID" : 73,
      "context" : "[79] reported the preparation of presumably functional 327 chitin nanoparticles and their application as reinforcing fillers in polymeric matrices.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 74,
      "context" : "It is used as a constituent of wound-healing dressings, exhibits good 330 biocompatibility and can be synthesized from chitin [80].",
      "startOffset" : 126,
      "endOffset" : 130
    }, {
      "referenceID" : 75,
      "context" : "[81] prepared CMC 331 nanoparticles using the cross-linking approach with FeCl3 and CaCl2 that was used for controlled 332",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 76,
      "context" : "[82] demonstrated novel amorphous chitin nanoparticles (AC NPs) 335 that were widely used for colon cancer drug delivery.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 77,
      "context" : "To deliver drugs into the intracellular compartments, numerous drugs encapsulated in 342 nanoparticles and microparticles were prepared, which showed enhanced efficacy in delivering 343 the drug into the intracellular compartments [83].",
      "startOffset" : 231,
      "endOffset" : 235
    }, {
      "referenceID" : 78,
      "context" : "[84], designed rifampicin (RIF)344 loaded AC Nps for intracellular delivery of RIF inside polymorphonuclear leukocytes.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 79,
      "context" : "Besides this unique 360 characteristic, CS has been evidenced to have various other intrinsic properties, namely good 361 biocompatibility and biodegradability and non-toxicity [85].",
      "startOffset" : 177,
      "endOffset" : 181
    }, {
      "referenceID" : 80,
      "context" : "Nowadays, CS has attracted 362 considerable scientific interest and nanotechnological attention in the biomedical sector for 363 various applications, including tissue engineering [86], drug delivery [87] and nutrition [88].",
      "startOffset" : 180,
      "endOffset" : 184
    }, {
      "referenceID" : 81,
      "context" : "Nowadays, CS has attracted 362 considerable scientific interest and nanotechnological attention in the biomedical sector for 363 various applications, including tissue engineering [86], drug delivery [87] and nutrition [88].",
      "startOffset" : 200,
      "endOffset" : 204
    }, {
      "referenceID" : 82,
      "context" : "Nowadays, CS has attracted 362 considerable scientific interest and nanotechnological attention in the biomedical sector for 363 various applications, including tissue engineering [86], drug delivery [87] and nutrition [88].",
      "startOffset" : 219,
      "endOffset" : 223
    }, {
      "referenceID" : 83,
      "context" : "[89] reported the CS- and CS-gold nanoconjugates of salmon leutinizing 365 hormone releasing hormone (LHRH) of desired size, dispersity, and zeta potential were 366 synthesized and evaluated at half the dose rate against full dose of bare LHRH for their 367 reproductive efficacy in female fish, Cyprinus carpio.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 84,
      "context" : "[90] reported the potential of CS nanoparticles as a delivery system for DOX.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 85,
      "context" : "[91] prepared dextran-DOX encapsulated in CS nanoparticles using reverse 377 microemulsion and studied their antitumor activity in murine tumor models.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 86,
      "context" : "[92] demonstrated the potential use of CS nanoparticles as a novel carrier for the targeted 379 delivery of drugs to the ocular mucosa, using the immunosuppressive peptide cyclosporin A as a 380",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 87,
      "context" : "The particle size at infinite dilution was 30 nm, when 383 10% of the amine groups in the polymeric chains were cross-linked and it shoots up to 110 nm 384 when all the amine groups were cross-linked [93].",
      "startOffset" : 200,
      "endOffset" : 204
    }, {
      "referenceID" : 88,
      "context" : "[94] showed the in vitro antibacterial activity of CS nanoparticles and copper386 loaded nanoparticles against pathogenic microorganisms.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 89,
      "context" : "[95] studied polyanion-initiated gelation process in fabricating 390 CS–tripolyphosphate nanoparticles in the size range from 100 to 250 nm, intended to be used as 391 carriers for the delivery of gene or protein macromolecules.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 90,
      "context" : "Katas and Alpar [96] developed CS 392 nanoparticles as a delivery system for double-stranded small interfering RNA (siRNA).",
      "startOffset" : 16,
      "endOffset" : 20
    }, {
      "referenceID" : 91,
      "context" : "[97] showed that hydrophobically modified glycol chitosan (HGC) 399 nanoparticles encapsulated camptothecin (CPT) with a high loading efficiency and CPT–HGC 400",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 92,
      "context" : "[98] demonstrated 404 the synthesis and characterization of CS and silver-loaded CS nanoparticles for antimicrobial 405 textile applications.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 94,
      "context" : "fabricate self-assembled polymeric nanoparticles and therefore facilitate drug delivery in cancer 421 therapy by improving the solubility of insoluble drugs, drug targeting, and absorption [101].",
      "startOffset" : 189,
      "endOffset" : 194
    }, {
      "referenceID" : 95,
      "context" : "[102] prepared magnetic nanoparticles consisting of iron oxide cores modified 423",
      "startOffset" : 0,
      "endOffset" : 5
    }, {
      "referenceID" : 96,
      "context" : "[103] prepared CS oligosaccharide-stabilized ferrimagnetic iron oxide 427 nanocubes (Chito-FIONs) as an effective heat nanomediator for cancer hyperthermia.",
      "startOffset" : 0,
      "endOffset" : 5
    }, {
      "referenceID" : 97,
      "context" : "[104] investigated a novel multidentate dithiolane lipoic acid and phosphorylcholine 432 conjugated CS oligosaccharide derivative that can serve as a ligand to effectively stabilize gold 433 nanoparticles.",
      "startOffset" : 0,
      "endOffset" : 5
    }, {
      "referenceID" : 98,
      "context" : "434 [105] prepared the COS nanoparticles by the formation of polyelectrolyte complexes.",
      "startOffset" : 4,
      "endOffset" : 9
    }, {
      "referenceID" : 99,
      "context" : "[106] prepared the synthesis of COS-based multidentate ligand for ultrastable, 437 cytotoxicity and biocompatible nanoparticles.",
      "startOffset" : 0,
      "endOffset" : 5
    }, {
      "referenceID" : 100,
      "context" : "polysaccharides, are attracting more and more attention all over the world [107].",
      "startOffset" : 75,
      "endOffset" : 80
    }, {
      "referenceID" : 102,
      "context" : "for research because of their high antimicrobial potential [109].",
      "startOffset" : 59,
      "endOffset" : 64
    }, {
      "referenceID" : 104,
      "context" : "[111] reported the synthesis and characterization of silver 459",
      "startOffset" : 0,
      "endOffset" : 5
    }, {
      "referenceID" : 105,
      "context" : "[112] reported the green synthesis of silver nanoparticles using marine 464",
      "startOffset" : 0,
      "endOffset" : 5
    }, {
      "referenceID" : 106,
      "context" : "using nanomaterials to reduce toxicity, dosing frequency, and avoiding potential side effects and 472 until now do not understand that delivery systems themselves may impose risks to the patient 473 [113].",
      "startOffset" : 199,
      "endOffset" : 204
    }, {
      "referenceID" : 107,
      "context" : "[114] studied the in vitro and in vivo effects of CS nanoparticles as a 474 novel drug delivery system for the ocular mucosa.",
      "startOffset" : 0,
      "endOffset" : 5
    }, {
      "referenceID" : 66,
      "context" : "[72] studied the 478 biosynthesis of gold nanoparticles using porphyran and the subsequent loading of DOX.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 108,
      "context" : "[116] reported a nanocarrier based on CS and fucoidan for oral delivery of 481 berberine (Ber).",
      "startOffset" : 0,
      "endOffset" : 5
    }, {
      "referenceID" : 93,
      "context" : "To achieve this aim, a number of hurdles are to be overcome by the gene delivery device 491 [100].",
      "startOffset" : 92,
      "endOffset" : 97
    }, {
      "referenceID" : 109,
      "context" : "However, as has been stated above, CS–DNA 496 nanoparticles may be readily formed by complex coacervation between the positively charged 497 amine groups on CS and negatively charged phosphate groups on DNA [118].",
      "startOffset" : 207,
      "endOffset" : 212
    }, {
      "referenceID" : 110,
      "context" : "[119] investigated that CS–polyguluronate nanoparticles exhibited low cytotoxicity and 505 were useful in delivering siRNA to HEK 293 FT and HeLa cells.",
      "startOffset" : 0,
      "endOffset" : 5
    }, {
      "referenceID" : 110,
      "context" : "These nanoparticles have a 506 great promise for siRNA delivery because of their low cytotoxicity and ability to transport 507 siRNA into cells [119].",
      "startOffset" : 144,
      "endOffset" : 149
    }, {
      "referenceID" : 111,
      "context" : "[121] prepared a novel fibrous membrane of carboxymethyl chitin 518 (CMC)/poly (vinyl alcohol) (PVA) blend using electrospinning technique.",
      "startOffset" : 0,
      "endOffset" : 5
    }, {
      "referenceID" : 112,
      "context" : "[122] prepared CS–gelatin/nanophase hydroxyapatite composite scaffolds by blending CS 523 and gelatin with nanophase hydroxyapatite.",
      "startOffset" : 0,
      "endOffset" : 5
    }, {
      "referenceID" : 113,
      "context" : "nanoparticles exhibited higher cytotoxicity to DOX alone [123].",
      "startOffset" : 57,
      "endOffset" : 62
    }, {
      "referenceID" : 114,
      "context" : "Cytotoxic activity exhibited that 538 the paclitaxel-loaded CS nanoparticles had higher cell toxicity than individual paclitaxel, and 539 confocal microscopy analysis confirmed strong cellular uptake efficiency [124].",
      "startOffset" : 211,
      "endOffset" : 216
    }, {
      "referenceID" : 45,
      "context" : "[49] 540 studied the DOX-loading fucoidan acetate nanoparticles for immunotherapy and chemotherapy 541 in cancer treatment.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 45,
      "context" : "Acetate nanoparticles have important functions, namely immunomodulation 542 and drug efflux pump inhibition [49].",
      "startOffset" : 108,
      "endOffset" : 112
    }, {
      "referenceID" : 115,
      "context" : "Currently, silver nanoparticles have come up as a more efficient bactericidal agent 549 and are finding various biomedical applications ranging from silver-based dressing to silver550 coated therapeutic devices [125].",
      "startOffset" : 211,
      "endOffset" : 216
    }, {
      "referenceID" : 116,
      "context" : "[126] prepared the 552 collagen-CS complex nanofibers by electrospinning.",
      "startOffset" : 0,
      "endOffset" : 5
    }, {
      "referenceID" : 19,
      "context" : "[22] have incorporated silver nanoparticles 554",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 117,
      "context" : "Biosensors 560 Biosensors have been of special interest in recent years because of their advantageous 561 properties as analytical tools such as simple, portable, low cost, well-established, and laboratory562 based methods as well as allows miniaturization [127].",
      "startOffset" : 257,
      "endOffset" : 262
    }, {
      "referenceID" : 118,
      "context" : "This system can be used for biosensors [128].",
      "startOffset" : 39,
      "endOffset" : 44
    }, {
      "referenceID" : 119,
      "context" : "[129] investigated a new 567 electrochemical tyrosinase biosensor for determining phenolic compounds on the basic of the use 568 of a glassy carbon electrode modified with tyrosinase–Fe3O4 magnetic nanoparticles-CS 569 nanobiocomposite film.",
      "startOffset" : 0,
      "endOffset" : 5
    }, {
      "referenceID" : 119,
      "context" : "Such 570 novel tyrosinase biosensor exhibits great promise for fast, simple, and eco-friendly methods of 571 phenolic contaminants in environmental samples [129].",
      "startOffset" : 156,
      "endOffset" : 161
    }, {
      "referenceID" : 120,
      "context" : "[130] developed an 572 amperometric biosensor for the determination of glutathione (GSH) by covalently immobilizing 573 a glutathione oxidase (GSHOx) onto the surface of gold-coated magnetic nanoparticles 574 (Fe@AuNPs)-modified Pt electrode.",
      "startOffset" : 0,
      "endOffset" : 5
    }, {
      "referenceID" : 121,
      "context" : "Chitin and CS have been widely studied in the removal of heavy metal 580 ions from wastewater [131].",
      "startOffset" : 94,
      "endOffset" : 99
    }, {
      "referenceID" : 122,
      "context" : "[132] investigated and found that the CS bead581",
      "startOffset" : 0,
      "endOffset" : 5
    }, {
      "referenceID" : 123,
      "context" : "The properties associated with the 593 nanometric dimensions and the presence of biological signals on polymeric chains may be 594 exploited in applications with antimicrobial activities and molecular biosensors [133].",
      "startOffset" : 212,
      "endOffset" : 217
    }, {
      "referenceID" : 124,
      "context" : "The 595 nanocomposite materials in the form of three-dimensional structure formed by a polymeric 596 matrix consisting of a polysaccharidic composition of neutral or anionic polysaccharides and 597 branched cationic polysaccharides, in which metallic nanoparticles are uniformly dispersed and 598 stabilized, has also been claimed [134].",
      "startOffset" : 331,
      "endOffset" : 336
    } ],
    "year" : 2015,
    "abstractText" : "10 Research on marine polysaccharide-based nanomaterials is emerging in nanobiotechnological 11 fields such as drug delivery, gene delivery, tissue engineering, cancer therapy, wound dressing, 12 biosensors, and water treatment. Important properties of the marine polysaccharides include 13 biocompatibility, biodegradability, nontoxicity, low cost, and abundance. Most of the marine 14 polysaccharides are derived from natural sources such as fucoidan, alginates, carrageenan, 15 agarose, porphyran, ulvan, mauran, chitin, chitosan, and chitooligosaccharide. Marine 16 polysaccharides are very important biological macromolecules that widely exist in marine 17 organisms. Marine polysaccharides exhibit a vast variety of structures and are still under18 exploited and thus should be considered as a novel source of natural products for drug discovery. 19 An enormous variety of polysaccharides can be extracted from marine organisms such as algae, 20 crustaceans, and microorganisms. Marine polysaccharides have been shown to have a variety of 21",
    "creator" : "Elsevier"
  }
}